Fluid drainage or delivery device for a treatment site

JP2023550635A5Inactive Publication Date: 2024-12-03AROA BIOSURGERY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023531049
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2021-11-16
Filing Date
2021-11-24
Publication Date
2024-12-03
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current solutions for fluid drainage and dead space reduction in surgical wounds, such as sutures, surgical drains, and tissue adhesives, are inadequate in effectively eliminating dead space and preventing seroma or hematoma formation, which can impede recovery and lead to infection or the need for additional surgery.

Method used

A bioabsorbable elastic truss device with intersecting elongated wall members and bracing members forms a channel for fluid drainage or delivery, maintaining structural integrity under stress and strain, and is combined with a flexible bioabsorbable sheet to facilitate fluid flow, connected to a pressure source for negative or positive pressure application.

Benefits of technology

The device effectively reduces dead space, enhances fluid evacuation, and allows for targeted fluid delivery to aid wound healing, minimizing inflammation and maintaining wound integrity by conforming to tissue contours and preventing channel collapse.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

A bioabsorbable device for implantation within a patient's body for administering fluid and / or negative pressure to a treatment site. The device includes a bioabsorbable elastic truss for holding two tissue surfaces apart. The truss has two flexible, elongated wall members wound in a manner to define a channel, the two elongated wall members periodically crossing each other at a plurality of crossing nodes. The truss also includes at least two flexible, elongated bracing members, each bracing member mechanically coupled to the two elongated wall members at the plurality of crossing nodes.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to a device for implantation for the drainage of fluid from or the delivery of fluid to a treatment site. Specifically, the device is bioabsorbable. The present invention further relates to a system and method for draining fluid from or delivering fluid to a treatment site using the device of the present invention, and a method for manufacturing the device.

Background Art

[0002] The drainage of fluid from surgical or traumatic wounds and the reduction of dead space are often important factors in the timely and effective recovery of patients. Currently, there is no good solution for eliminating dead space during surgery. Suturing provides a linear closure rather than a closure across the entire separated tissue plane. Surgical drains are only partially effective in removing fluid and do not address the major problem of closing dead space immediately after surgery. Tissue adhesives have not been proven to be consistently effective, and manually suturing across the entire area provides only a limited amount of local closure.

[0003] Seroma or hematoma formation after surgery or trauma can impede recovery. Seromas and hematomas are pockets of serous fluid or blood that accumulate at the wound site. Without proper drainage, poor healing, infection, or dehiscence can lead to the need for additional surgery and longer hospital stays. Seromas and hematomas are common after reconstructive plastic surgery, trauma, mastectomy, tumor resection, cesarean section, hernia repair, and incision surgery involving extensive tissue elevation and dissection.

[0004] Reducing dead space and providing drainage of fluid from the wound site is highly desirable in many cases, while in other situations, it can be useful to deliver fluid directly to the wound site to assist in the wound healing process. For example, an antibacterial solution can be locally instilled to prevent infection. Similarly, the instillation of a local anesthetic can assist in pain management.

[0005] The applicant’s earlier international application PCT / NZ2018 / 050134 discloses a device for implantation in a treatment site for draining fluid from the site or for delivering fluid to the site. The device comprises a bioabsorbable elastic truss for holding two separated tissue surfaces and defining a channel through which fluid can be drained from the treatment site or delivered to the treatment site.

[0006] Many of the trusses described in the patent application are manufactured by thermally bonding bioabsorbable polymer filaments. The bioabsorbable polymer filaments used in these trusses are polymers with a highly oriented microstructure. The process of thermally bonding the filaments alters the microstructure of the polymer at and adjacent to the bonding sites, typically by reducing the degree of orientation, thereby placing the material in a lower energy state in these regions. It has been found that these regions of the filament with altered microstructure are reabsorbed at a faster rate than portions of the filament with unaltered microstructure, meaning that the truss may break at the initially bonded region and lose its structural integrity. Thermal bonding can also cause the filaments to shrink and deform.

[0007] Furthermore, there is a need for implants that can withstand greater compressive forces (lateral, crushing type) to reduce the possibility of channel collapse, occlusion, or contraction while maintaining longitudinal flexibility. These characteristics are particularly important when the implant is placed in a region that is subjected to relatively high levels of stress and strain due to recipient movement.

[0008] Implantation of synthetic materials can contribute to elevated inflammatory levels, which typically occur in the body after implantation, particularly in sensitive vascular areas such as the pelvic floor or abdominal wall. Many bioabsorbable materials are also broken down and absorbed through a process of bulk hydrolysis, in which the polymer chains of the synthetic material absorb water and break down their chemical structure into various monomers. This releases harmful acids that can trigger elevated inflammatory and foreign body reactions, as seen with synthetic meshes commonly used in hernia abdominal wall repair and pelvic organ prolapse repair. Therefore, minimizing the amount of synthetic material used in implants is desirable.

[0009] Therefore, an object of the present invention is to provide a fluid discharge or delivery device that addresses one or more of the aforementioned drawbacks, and / or to provide at least a useful alternative to existing devices.

[0010] Where references are made herein to patent specifications, other external documents, or other sources, these are generally provided to offer context for considering the features of the present invention. Unless otherwise specified, references to such external documents or sources should not be construed as an admission in any jurisdiction that such documents or sources constitute prior art or form part of common sense in the art. [Overview of the project]

[0011] According to a first aspect, the invention described herein is broadly a bioabsorbable device for implantation in a patient's body to administer fluid and / or negative pressure to a treatment site, wherein the device comprises a bioabsorbable elastic truss for holding two separated tissue surfaces. The truss comprises two flexible elongated wall members wound in a manner defining a channel, the two elongated wall members periodically intersecting each other at a plurality of intersection nodes, and at least two flexible elongated bracing members, each bracing member mechanically connected to the two elongated wall members at a plurality of intersection nodes.

[0012] In one embodiment, the bracing member extends substantially longitudinally along the side of the channel.

[0013] In one embodiment, bracing truss members are provided on both sides of the channel.

[0014] In one embodiment, the wall member is wound to form a porous wall so that fluid from the treatment site can be discharged through the channel and / or the fluid can be delivered from the channel to the treatment site. The device may be substantially tubular in shape.

[0015] In one embodiment, each bracing member is mechanically connected to two elongated wall members at each intersection node by the respective bracing members looping around the wall member.

[0016] In one embodiment, each bracing member comprises a main filament that forms a complete 360-degree loop around the wall member at each intersection node. In some embodiments, the main filament of each bracing member may form a 720-degree loop around the wall member at each intersection node.

[0017] In one embodiment, each bracing member further comprises a secondary filament twisted around a main filament.

[0018] In one embodiment, each bracing member comprises two filaments twisted together, and a wall member is held between the two filaments at each intersection node.

[0019] In one embodiment, there is at least one complete twist of filaments between adjacent interconnected cross nodes.

[0020] In one embodiment, each bracing member is mechanically connected to two elongated wall members at each intersection node by wall members that loop around each bracing member.

[0021] In one embodiment, each elongated wall member is substantially helical. In one embodiment, the first wall member is substantially helical with a first pitch length, and the second wall member is substantially helical with a second pitch length which is the same as the first pitch length. The two helical wall members can be wound in opposite directions.

[0022] Alternatively, the first wall member among the wall members may be the left-side wall member, and the second wall member among the wall members may be the right-side wall member. Optionally, the truss may comprise two left-side wall members and two right-side wall members. The left and right wall members may meander between the bracing members in a non-spiral configuration.

[0023] In one embodiment, each wall member has a pitch length of approximately 2 mm to approximately 10 mm. Each wall member may have a pitch length of approximately 4 mm.

[0024] In one embodiment, the wall member and the bracing member include sutures.

[0025] In one embodiment, the truss forms a flexible tube having a circular or elliptical cross-section.

[0026] In one embodiment, the channel has a cross-sectional area of at least 16 mm 2 .

[0027] In one embodiment, the device further comprises a flexible bioabsorbable sheet, and the sheet forms at least a portion of the wall of the channel.

[0028] In one embodiment, the flexible bioabsorbable sheet is wrapped around the truss. The flexible bioabsorbable sheet may comprise a plurality of openings in the flexible bioabsorbable sheet to enable fluid flow into the channel.

[0029] In one embodiment, the device further comprises two flexible bioabsorbable sheets, and the channel is formed between the opposing surfaces of the two flexible sheets. A plurality of openings may be formed in one or both of the flexible sheets along the wall of the channel to enable fluid flow into the channel.

[0030] In such embodiments, the flexible sheet or each flexible sheet comprises one or more layers of extracellular matrix (ECM) or polymeric material. The ECM may be formed from the decellularized lamina propria-submucosa of the forestomach of a ruminant.

[0031] In one embodiment, the device comprises a port in fluid communication with one or more channels and connectable to a negative pressure source or a positive pressure source. Preferably, the port is connectable to a negative pressure source.

[0032] In one embodiment, the treatment site is the space between the surfaces of muscle tissue, connective tissue, or skin tissue that has been separated during surgery or as a result of an injury.

[0033] According to a second aspect, the present invention as described herein broadly relates to a system for draining fluid from or delivering fluid to a treatment site within a patient's body. The system comprises (i) a device according to a first aspect of the present invention; (ii) a conduit releasably coupled to either a port of the device or a fluid-impermeable covering; (iii) a reservoir located outside the patient's body, the reservoir being in fluid communication with the conduit for receiving fluid from or delivering fluid to the conduit; and (iv) a pressure source coupled to the conduit for delivering positive or negative pressure to the device.

[0034] In one embodiment, the pressure source can deliver negative pressure to the device so that fluid is discharged from the treatment site into the device and transferred to the reservoir through the conduit. Alternatively, the pressure source can deliver positive pressure to the device so that fluid in the reservoir is transferred through the conduit into the device and to the treatment site.

[0035] According to a third aspect, the present invention as described herein is broadly a method for draining fluid from or delivering fluid to a treatment site within a patient's body. The method includes (i) implanting a device according to a first aspect of the present invention at a treatment site; (ii) connecting a conduit to the device to receive fluid from or deliver fluid to the conduit to a reservoir located outside the patient's body; and (iii) delivering negative pressure to the device so that fluid is drained from the treatment site into the device and transferred through the conduit to the reservoir, or delivering positive pressure to the device so that fluid in the reservoir is transferred through the conduit into the device and to the treatment site.

[0036] In a fourth aspect, the present invention provides a system for treating a wound, comprising a fluid input and a fluid output for connection to a wound treatment device located in the wound. The wound treatment device may be as described above. The fluid input is adapted to be fluidly connected to the upstream side of the wound treatment device, and the fluid output is adapted to be fluidly connected to the downstream side of the wound treatment device. The system further comprises an air inlet valve upstream of the fluid output, an actuator for driving the air inlet valve between an open position and a closed position, a pump downstream of the fluid input, a motor for driving the pump to provide negative pressure to the wound treatment device, and a controller for communicating with the actuator and the motor to operate the air inlet valve and the pump. The controller is configured to i) open the air inlet valve and operate the pump to maintain a first vacuum pressure in the wound treatment device and introduce air into the wound treatment device, and ii) close the air inlet valve and operate the pump to maintain a second vacuum pressure in the wound treatment device and remove air and fluid from the wound treatment device. The first vacuum pressure is less than or equal to the second vacuum pressure.

[0037] In one embodiment, the controller is configured to operate a pump when the air valve is opened or closed, thereby continuously maintaining a negative pressure environment in the wound healing device.

[0038] In one embodiment, the first and second vacuum pressures provide effective negative pressure wound therapy.

[0039] In one embodiment, the controller is configured to cycle the air inlet valve between the open and closed positions by repeating steps i) and ii).

[0040] In one embodiment, the controller is configured to repeat steps i) and ii) to continuously cycle the air inlet valve between the open position and the closed position.

[0041] In one embodiment, the controller is configured to operate the pump when the air inlet valve is opened to maintain a substantially constant first vacuum pressure.

[0042] In one embodiment, the controller is configured to operate the pump with the air inlet valve open so that the flow rate of air into the system through the air inlet valve is equal to the flow rate of the pump.

[0043] In one embodiment, the controller is configured to operate the pump when the air inlet valve is closed to maintain a substantially constant second vacuum pressure.

[0044] In one embodiment, the controller is configured in step (i) to operate the pump with the air inlet valve open so that the system is in equilibrium with zero or constant pressure difference across the treatment device.

[0045] In one embodiment, the controller is configured in step (i) to operate the pump with the air inlet valve closed so that the system is in equilibrium with zero or constant pressure difference across the treatment device.

[0046] In one embodiment, the controller is configured to operate an air inlet valve between open and closed to introduce a flow rate of air into the system that generates a bubble or slug flow containing air bubbles or slug mixed in with the fluid flow from the wound healing device.

[0047] In one embodiment, the controller is configured to operate an air inlet valve between open and closed to reduce the fluid density in the wound and lift the fluid from the wound against gravity.

[0048] In one embodiment, the controller is configured to periodically open and close the air inlet valve.

[0049] In one embodiment, in step i), the controller is configured to open the air inlet valve for a predetermined period of time. In another embodiment, in step i), the controller is configured to open the air inlet valve for at least 10 seconds.

[0050] In one embodiment, in step ii), the controller is configured to close the air inlet valve for a predetermined period of time.

[0051] In one embodiment, the air inlet valve is open for at least 10% of the cycle pitch, or at least 20% of the cycle pitch, or at least 30% of the cycle pitch, or at least 40% of the cycle pitch, or at least 50% of the cycle pitch.

[0052] In one embodiment, in step (i), the air inlet valve is opened for a sufficient amount of time such that the volume of air delivered through the system is at least a substantial portion of the total volume of the system. For example, in step (i), the air inlet valve may be opened for a sufficient amount of time such that the volume of air delivered to the system is at least 50%, or at least 100%, of the total volume of the system.

[0053] In one embodiment, the first vacuum pressure is approximately 30% to 100% of the second vacuum pressure.

[0054] In one embodiment, the first vacuum pressure is about 50 to 100 mmHg, preferably about 80 to 90 mmHg.

[0055] In one embodiment, the second vacuum pressure is about 100 to 150 mmHg, preferably about 100 to 110 mmHg.

[0056] In one embodiment, the first vacuum pressure is approximately 10-50 mmHg lower than the second pressure.

[0057] In one embodiment, in step (i), the controller is configured to operate the pump to achieve a vacuum pressure threshold. In one embodiment, in step (ii), the controller is configured to operate the pump to achieve a vacuum pressure threshold.

[0058] In one embodiment, the system includes a downstream pressure sensor located downstream of the wound healing device and communicating with a controller. The controller may be configured in step i) to operate a pump to achieve a vacuum pressure threshold based on the pressure sensed by the downstream pressure sensor.

[0059] In one embodiment, the system includes an upstream pressure sensor located upstream of the wound healing device and communicating with a controller. The controller may be configured in step i) to operate a pump to achieve a vacuum pressure threshold based on the pressure sensed by the upstream pressure sensor.

[0060] In one embodiment, the system is An upstream pressure sensor located upstream of the wound healing device and communicating with the controller, A downstream pressure sensor located downstream of the wound healing device and communicating with the controller is included, In step i), the controller operates the pump to achieve a first vacuum pressure threshold based on the pressure sensed by the downstream pressure sensor. In step ii), the pump is configured to operate to achieve a second vacuum pressure threshold based on the pressure sensed by the upstream pressure sensor.

[0061] In one embodiment, the first vacuum pressure threshold is less than or equal to the second vacuum pressure threshold.

[0062] In one embodiment, the system includes an inlet throttling, and an upstream pressure sensor is located upstream of the inlet throttling such that the upstream pressure sensor measures ambient pressure when the air inlet valve is open.

[0063] In one embodiment, the system includes an inlet throttling for presenting a predetermined pressure drop between ambient pressure and vacuum pressure in the wound healing device.

[0064] In one embodiment, the system includes a filter for filtering the air introduced into the system, the filter being or comprising an inlet throttling.

[0065] In one embodiment, the pressure drop is approximately 20 to 130 mmHg.

[0066] In one embodiment, when the air inlet valve is opened, substantially all of the pressure difference between the ambient pressure and the pressure downstream of the wound healing device is at the inlet throttling.

[0067] In one embodiment, the system includes a reservoir for collecting fluid removed from the wound, and the reservoir is located downstream of the pump so that the fluid removed from the wound is sent to the reservoir through the pump.

[0068] In one embodiment, the reservoir includes a flexible bag.

[0069] In one embodiment, the reservoir is provided with vents for ventilating the reservoir to the surrounding atmosphere.

[0070] In one embodiment, the system includes a therapeutic fluid inlet upstream of the fluid outlet for connecting the supply of therapeutic fluid.

[0071] In one embodiment, the system is configured such that, in step i), the introduction of a treatment fluid into the wound treatment device is prevented or reduced by the introduction of air into the wound treatment device by a first vacuum pressure, and in step ii), the treatment fluid is drawn into the wound treatment device by a second vacuum pressure.

[0072] In one embodiment, the system is A treatment fluid valve between the treatment fluid inlet and the fluid outlet, The system includes an actuator that drives a treatment fluid inlet valve between an open position and a closed position, and the controller communicates with the fluid inlet valve actuator, and the controller, in a fluid supply state, iii) Open the fluid inlet valve and operate the pump to maintain vacuum pressure in the wound healing device and introduce the healing fluid into the wound healing device. iv) The fluid inlet valve is closed and the pump is operated to maintain vacuum pressure in the wound healing device and remove fluid from the wound healing device.

[0073] In one embodiment, the controller is configured to operate a pump when the fluid inlet valve is opened or closed, thereby continuously maintaining a negative pressure environment in the wound healing device.

[0074] In one embodiment, the controller is configured to operate a pump in step (iii) to generate a third vacuum pressure in the wound healing device, and to operate a pump in step (iv) to generate a fourth vacuum pressure in the wound healing device, wherein the third vacuum pressure is less than or equal to the fourth vacuum pressure.

[0075] In one embodiment, the third vacuum pressure is equal to or similar to the first vacuum pressure, and the fourth vacuum pressure is equal to or similar to the second vacuum pressure.

[0076] In one embodiment, third and fourth vacuum pressures provide effective negative pressure wound therapy.

[0077] In one embodiment, after closing the fluid inlet valve and operating the pump to generate vacuum pressure in the wound, the controller... (v) It is configured to wash away the healing fluid from the wound, which is, (v)(a) Open the air inlet valve and operate the pump to maintain a vacuum pressure (e.g., a first vacuum pressure) in the wound healing device and introduce air into the wound healing device, (v)(b) By closing the air inlet valve and operating the pump to maintain a vacuum pressure (e.g., a second vacuum pressure) in the wound healing device and removing fluid from the wound healing device.

[0078] In one embodiment, in step (v), the controller is configured to repeat steps (v)(a) and (v)(b) a predetermined number of times (for example, 3 times) in order to remove the therapeutic fluid from the wound.

[0079] In one embodiment, during fluid therapy, the controller is configured to repeat steps (iii) to (v) a predetermined number of times.

[0080] In one embodiment, the controller is configured in step (iv) to close the fluid inlet valve, wait for a predetermined time, and operate the pump to generate vacuum pressure in the wound healing device and remove fluid from the wound healing device.

[0081] In one embodiment, the controller is configured to periodically activate the fluid supply state.

[0082] In one embodiment, the time required to activate the fluid supply state is much longer than the cycle time of the air inlet valve.

[0083] In one embodiment, the system comprises an upstream pressure sensor and / or a downstream pressure sensor that communicate with a controller, and in step (iii), the controller is configured to operate the pump to achieve a vacuum pressure threshold based on the pressures sensed by the upstream and / or downstream pressure sensors.

[0084] In one embodiment, the system comprises an upstream pressure sensor and / or a downstream pressure sensor that communicate with a controller, and in step (iv), the controller is configured to operate the pump to achieve a vacuum pressure threshold based on the pressures sensed by the upstream and / or downstream pressure sensors.

[0085] The present invention can also be broadly said to consist of any combination of any two or more such parts, elements, and features, individually or collectively, as referred to or shown in the specification of this application. Where any particular integer having known equivalents in the art relating to the present invention is referred to herein, such known equivalents shall be deemed incorporated herein as if they were described separately.

[0086] As used herein and in the claims, the term “contains” means “consisting of at least part of.” When interpreting any description in this specification and in the claims that contains the term “contains,” other features that do not begin with this term may also exist. Related terms such as “contains” and “included” are interpreted similarly.

[0087] References to numerical ranges disclosed herein (e.g., 1 to 10) are intended to also incorporate references to all rational numbers within that range and to any range of rational numbers within that range (e.g., 1 to 6, 1.5 to 5.5, and 3.1 to 10). Accordingly, all subranges of all ranges expressly disclosed herein are expressly disclosed herein.

[0088] As used herein, the term "(plural)" following a noun means the plural and / or singular forms of that noun. As used herein, the term "and / or" means "and" or "or," or both, where the context allows. [Brief explanation of the drawing]

[0089] Herein, the present invention will be described only by reference to the accompanying drawings. [Figure 1] This is a right-hand perspective view showing a truss structure of the first embodiment having an indeterminate length. [Figure 2] This is a left-hand perspective view showing the truss structure in Figure 1, where the truss has an indeterminate length. [Figure 3]This is a side view corresponding to Figure 1 and Figure 2. [Figure 4] Figures 1 to 3 show end views (or cross-sectional views) of the embodiments. [Figure 5] Figures 1 to 4 are plan views of the embodiments. [Figure 6] This is a right-hand perspective view showing a truss structure of a second embodiment having an indeterminate length. [Figure 7] This is a left-hand perspective view showing the truss structure in Figure 6, where the truss has an indeterminate length. [Figure 8] This is a side view corresponding to Figure 6 and Figure 7. [Figure 9] Figures 6 to 8 show end views (or cross-sectional views) of the embodiments. [Figure 10] Figures 6 to 9 are plan views of the embodiments. [Figure 11] Figures 6 to 10 are perspective views illustrating the steps for manufacturing the first wall member of the truss. [Figure 12] Figures 6 to 10 are perspective views illustrating the steps for manufacturing the second wall member in the truss embodiment. [Figure 13] Figures 6 to 10 illustrate a perspective view illustrating the first step in forming the first bracing member among the bracing members in the truss. [Figure 14] This is a side view illustrating the second step for forming the first bracing member among the bracing members in the truss shown in Figures 6 to 10. [Figure 15] This is a perspective view illustrating the second step in Figure 14. [Figure 16] This is a perspective view showing a partially fabricated truss with one bracing member. [Figure 17] This is a right-hand perspective view showing a truss structure of a third embodiment having an uncertain length, with the top and bottom bracing members partially cut out for clarity. [Figure 18]Figure 17 is a left-hand perspective view showing the truss structure, in which the truss has an indeterminate length, and the top and bottom bracing members are partially cut out for clarity. [Figure 19] These are side views corresponding to Figures 17 and 18, illustrating the winding of the bracing member. [Figure 20] Figures 17 to 19 show end views (or cross-sectional views) of the embodiments. [Figure 21] Figures 17 to 20 are plan views of the embodiments. [Figure 22] This is a right-hand perspective view showing a truss structure of a fourth embodiment having an indeterminate length. [Figure 23] This is a left-hand perspective view showing the truss structure in Figure 22, where the truss has an indeterminate length. [Figure 24] These are side views corresponding to Figures 22 and 23. [Figure 25] Figures 22 to 24 show end views (or cross-sectional views) of the embodiments. [Figure 26] Figures 22 to 25 are plan views of the embodiments. [Figure 27] This is a plan view illustrating an exemplary truss connection between an inlet conduit and an outlet conduit for use in a wound healing system. [Figure 28] This diagram corresponds to Figure 27, showing a truss that has been disconnected from the conduit. [Figure 29] For clarity, the conduit and connecting sleeve are shown in a cross-sectional view; this is a side view illustrating one method of connecting an exemplary truss to a conduit. [Figure 30] Figure 27 is a side view of the truss and conduit connections. [Figure 31] This is a left-side perspective view of a truss structure of a fifth embodiment having an indeterminate length. [Figure 32] This is a right-hand perspective view of the embodiment shown in Figure 31. [Figure 33] Figures 31 and 32 are top views of a portion of the truss illustrating the winding of the truss wall members. [Figure 34]Figures 31 to 33 are side views of a portion of a truss, illustrating the winding of a truss wall member. [Figure 35] Figures 31 to 34 show the end view (or cross-sectional view) of the truss. [Figure 36(i)] Figures 31 to 35 illustrate the first step in manufacturing the truss, with Figure 36(i) being a top view, Figure 36(ii) a side view, Figure 36(iii) an end view, and Figure 36(iv) a perspective view. [Figure 36(ii)] Figures 31 to 35 illustrate the first step in manufacturing the truss, with Figure 36(i) being a top view, Figure 36(ii) a side view, Figure 36(iii) an end view, and Figure 36(iv) a perspective view. [Figure 36(iii)] Figures 31 to 35 illustrate the first step in manufacturing the truss, with Figure 36(i) being a top view, Figure 36(ii) a side view, Figure 36(iii) an end view, and Figure 36(iv) a perspective view. [Figure 36(iv)] Figures 31 to 35 illustrate the first step in manufacturing the truss, with Figure 36(i) being a top view, Figure 36(ii) a side view, Figure 36(iii) an end view, and Figure 36(iv) a perspective view. [Figure 37(i)] Figures 31 to 35 illustrate the second step in the fabrication of the truss, with Figure 37(i) being a top view, Figure 37(ii) a side view, Figure 37(iii) an end view, and Figure 37(iv) a perspective view. [Figure 37(ii)] Figures 31 to 35 illustrate the second step in the fabrication of the truss, with Figure 37(i) being a top view, Figure 37(ii) a side view, Figure 37(iii) an end view, and Figure 37(iv) a perspective view. [Figure 37(iii)] Figures 31 to 35 illustrate the second step in the fabrication of the truss, with Figure 37(i) being a top view, Figure 37(ii) a side view, Figure 37(iii) an end view, and Figure 37(iv) a perspective view. [Figure 37(iv)] Figures 31 to 35 illustrate the second step in the fabrication of the truss, with Figure 37(i) being a top view, Figure 37(ii) a side view, Figure 37(iii) an end view, and Figure 37(iv) a perspective view. [Figure 38(i)]Figures 31 to 35 illustrate the third step in the fabrication of the truss, with Figure 38(i) being a top view, Figure 38(ii) a side view, Figure 38(iii) an end view, and Figure 38(iv) a perspective view. [Figure 38(ii)] Figures 31 to 35 illustrate the third step in the fabrication of the truss, with Figure 38(i) being a top view, Figure 38(ii) a side view, Figure 38(iii) an end view, and Figure 38(iv) a perspective view. [Figure 38(iii)] Figures 31 to 35 illustrate the third step in the fabrication of the truss, with Figure 38(i) being a top view, Figure 38(ii) a side view, Figure 38(iii) an end view, and Figure 38(iv) a perspective view. [Figure 38(iv)] Figures 31 to 35 illustrate the third step in the fabrication of the truss, with Figure 38(i) being a top view, Figure 38(ii) a side view, Figure 38(iii) an end view, and Figure 38(iv) a perspective view. [Figure 39(i)] Figures 31 to 35 illustrate the fourth step in the fabrication of the truss, with Figure 39(i) being a top view, Figure 39(ii) a side view, Figure 39(iii) an end view, and Figure 39(iv) a perspective view. [Figure 39(ii)] Figures 31 to 35 illustrate the fourth step in the fabrication of the truss, with Figure 39(i) being a top view, Figure 39(ii) a side view, Figure 39(iii) an end view, and Figure 39(iv) a perspective view. [Figure 39(iii)] Figures 31 to 35 illustrate the fourth step in the fabrication of the truss, with Figure 39(i) being a top view, Figure 39(ii) a side view, Figure 39(iii) an end view, and Figure 39(iv) a perspective view. [Figure 39(iv)] Figures 31 to 35 illustrate the fourth step in the fabrication of the truss, with Figure 39(i) being a top view, Figure 39(ii) a side view, Figure 39(iii) an end view, and Figure 39(iv) a perspective view. [Figure 40] This is a rear perspective view of an apparatus for manufacturing trusses of various embodiments described herein. [Figure 41] Figure 40 is a front perspective view of the manufacturing apparatus. [Figure 42]Figures 40 and 41 are front views of the manufacturing apparatus. [Figure 43] Figures 40 to 42 are disassembled rear perspective views of the manufacturing equipment. [Figure 44A] Figures 40 to 43 illustrate the use of the manufacturing apparatus in the first step of fabricating the embodiments shown in Figures 31 to 35, with Figure 44A being a perspective view of the apparatus setup, and Figure 44B being a cross-sectional view through the mandrel for the truss illustrating the first step of winding filaments around the mandrel and bracing members. [Figure 44B] Figures 40 to 43 illustrate the use of the manufacturing apparatus in the first step of fabricating the embodiments shown in Figures 31 to 35, with Figure 44A being a perspective view of the apparatus setup, and Figure 44B being a cross-sectional view through the mandrel for the truss illustrating the first step of winding filaments around the mandrel and bracing members. [Figure 45A] Figures 40-43 illustrate the use of the manufacturing apparatus in the second step of fabricating the embodiments shown in Figures 31-35, where Figure 45A is a perspective view of the apparatus setup, and Figure 45B is a cross-sectional view through the mandrel for the truss illustrating the second step of winding the filament around the mandrel. [Figure 45B] Figures 40-43 illustrate the use of the manufacturing apparatus in the second step of fabricating the embodiments shown in Figures 31-35, where Figure 45A is a perspective view of the apparatus setup, and Figure 45B is a cross-sectional view through the mandrel for the truss illustrating the second step of winding the filament around the mandrel. [Figure 46A] Figures 40-43 illustrate the use of the manufacturing apparatus in the third step of fabricating the embodiments shown in Figures 31-35, with Figure 46A being a perspective view of the apparatus setup and Figure 46B being a cross-sectional view through the mandrel for the truss illustrating the third step of winding the filament around the mandrel. [Figure 46B]Figures 40-43 illustrate the use of the manufacturing apparatus in the third step of fabricating the embodiments shown in Figures 31-35, with Figure 46A being a perspective view of the apparatus setup and Figure 46B being a cross-sectional view through the mandrel for the truss illustrating the third step of winding the filament around the mandrel. [Figure 47A] Figures 40-43 illustrate the use of the manufacturing apparatus in the fourth step of fabricating the embodiments shown in Figures 31-35, with Figure 47A being a perspective view of the apparatus setup, Figure 47B being a perspective view of a portion of the wound truss wall member, and Figure 47C being a cross-sectional view through the mandrel for the truss illustrating the fourth step of winding the filament around the mandrel. [Figure 47B] Figures 40-43 illustrate the use of the manufacturing apparatus in the fourth step of fabricating the embodiments shown in Figures 31-35, with Figure 47A being a perspective view of the apparatus setup, Figure 47B being a perspective view of a portion of the wound truss wall member, and Figure 47C being a cross-sectional view through the mandrel for the truss illustrating the fourth step of winding the filament around the mandrel. [Figure 47C] Figures 40-43 illustrate the use of the manufacturing apparatus in the fourth step of fabricating the embodiments shown in Figures 31-35, with Figure 47A being a perspective view of the apparatus setup, Figure 47B being a perspective view of a portion of the wound truss wall member, and Figure 47C being a cross-sectional view through the mandrel for the truss illustrating the fourth step of winding the filament around the mandrel. [Figure 48A] Figures 40-43 illustrate the use of the manufacturing apparatus in the fifth step when fabricating the embodiments shown in Figures 31-35, Figure 48A is a perspective view of the apparatus setup, Figure 48B is a perspective view of a portion of the wound truss wall member, and Figure 48C is a cross-sectional view through the mandrel for the truss illustrating the fifth step of winding the filament around the mandrel. [Figure 48B]Figures 40-43 illustrate the use of the manufacturing apparatus in the fifth step when fabricating the embodiments shown in Figures 31-35, Figure 48A is a perspective view of the apparatus setup, Figure 48B is a perspective view of a portion of the wound truss wall member, and Figure 48C is a cross-sectional view through the mandrel for the truss illustrating the fifth step of winding the filament around the mandrel. [Figure 48C] Figures 40-43 illustrate the use of the manufacturing apparatus in the fifth step when fabricating the embodiments shown in Figures 31-35, Figure 48A is a perspective view of the apparatus setup, Figure 48B is a perspective view of a portion of the wound truss wall member, and Figure 48C is a cross-sectional view through the mandrel for the truss illustrating the fifth step of winding the filament around the mandrel. [Figure 49] This is a left-side perspective view of a truss structure of a sixth embodiment having an indeterminate length. [Figure 50] Figure 49 is a front right-side perspective view of the truss. [Figure 51] Figures 49 and 50 are side views of a portion of the truss illustrating the winding of the side truss wall members. [Figure 52] Figures 49 to 51 are top views of a portion of the truss. [Figure 53] Figures 49 to 52 show the end view (or cross-sectional view) of the truss. [Figure 54] This is a left side perspective view of a truss structure of a further embodiment having an indeterminate length. [Figure 55] This is a right-hand perspective view of the truss structure in Figure 54, where a portion of one of the truss members is hatched. [Figure 56] Figures 54 and 55 are side views of the truss structure, with one of the truss members hatched. [Figure 57] Figures 54 to 56 are top views of the truss structure, with a portion of one of the truss members hatched. [Figure 58] Figures 54 to 57 are end views of the cross-sectional views of the truss structure. [Figure 59(i)]Figures 27 to 30 illustrate a multi-lumen conduit that is divided to connect to a truss, Figure 59(i) illustrates a cutting line for separating the first and second lumens, and Figure 59(ii) is an end view illustrating the dual-lumen conduit of Figures 27 to 30, with the truss hidden. [Figure 59(ii)] Figures 27 to 30 illustrate a multi-lumen conduit that is divided to connect to a truss, Figure 59(i) illustrates a cutting line for separating the first and second lumens, and Figure 59(ii) is an end view illustrating the dual-lumen conduit of Figures 27 to 30, with the truss hidden. [Figure 60] This shows a bioabsorbable device with a truss that is placed inside the body of a patient where dead space exists, and is connected to a negative pressure source. [Figure 61] Figure 60 shows the result after the applied negative pressure has successfully closed the dead space at the treatment site. [Figure 62] Figures 60 and 61 show the installed bioabsorbable device after the conduit connecting the device to the negative pressure source has been removed following treatment. [Figure 63] Figures 60-62 show the treatment site at the time the bioabsorbable device was absorbed following the successful completion of the treatment. [Figure 64] This specification provides a high-level schematic diagram of a negative pressure treatment (NPT) system according to at least one embodiment described herein. [Figure 65] Figure 60 illustrates the system applied to internal wounds. [Figure 66] Figure 60 is a schematic diagram of the vacuum unit of the system. [Figure 67] Figure 64 is a schematic diagram of the system. [Figure 68] This is a schematic diagram of a negative pressure therapy (NPT) system of a further embodiment. [Figure 69] This is a schematic diagram of a further alternative embodiment of a negative pressure therapy (NPT) system. [Figure 70]This illustrates various flow characteristics when air is mixed into a liquid flow. [Figure 71] This specification provides high-level control flow diagrams for various embodiments of the negative pressure therapy (NPT) systems described herein. [Figure 72] The control flow diagrams for the airflow state in Figures 71 and 76 are provided. [Figure 73] The control flow diagrams for the pressurized state in Figures 71 and 76 are provided. [Figure 74] Figure 67 provides a control flow diagram for the holding pressure state in the control flow diagram. [Figure 75] The control flow diagrams for the timeout state in Figures 71 and 76 are provided. [Figure 76] This specification provides high-level control flow diagrams for various embodiments of the NPWT system described herein. [Figure 77] A control flow diagram for the holding pressure state in the control flow diagram of Figure 76 is provided. [Figure 78] Figure 76 provides a control flow diagram for the fluid flow state in the control flow diagram. [Figure 79] Figure 76 provides a control flow diagram for the flushing cycle of the fluid flow state. [Figure 80] This provides a chart showing the system performance of the treatment system test setup. [Modes for carrying out the invention]

[0090] definition As used herein, the term “bioresorbable” means that the body can break it down and absorb or rebuild it, and therefore does not need to be removed manually.

[0091] As used herein, the term “treatment site” means a site in the human or animal body where the surface of muscle tissue, connective tissue, or skin tissue is separated during surgery or as a result of trauma or removal.

[0092] As used herein, the term “lamina propria-submucosa” refers to the tissue structure formed by the mixing of the lamina propria and submucosa in the forestomach of ruminants.

[0093] As used herein, the term “lamina propria” refers to the luminal portion of the lamina propria-submucosa, including the lamina compacta of the extracellular matrix.

[0094] As used herein, the term “extracellular matrix” (ECM) refers to decellularized animal or human tissue that provides a matrix for structural integrity and a framework for supporting other materials.

[0095] As used herein, the term “decellularized” refers to the removal of cells and their associated debris from a portion of a tissue or organ, for example, from the extracellular matrix (ECM).

[0096] As used herein, the term “spiral” generally refers to a spiral shape, which may relate to shapes having a circular cross-section, but may also refer to shapes having a non-circular cross-section.

[0097] As used herein, the term “polymer material” refers to a large molecule or macromolecule containing many repeating subunits and may be a natural material including, but not limited to, polypeptides and proteins (e.g., collagen), polysaccharides (e.g., alginates), and other biopolymers such as glycoproteins, or a synthetic material including, but not limited to, polyglycolic acid, polylactic acid, P4HB (Poly-4-hydroxybutyrate), polylactic acid and polyglycolic acid copolymers, polycaprolactone, and polydioxanone.

[0098] device Herein, various embodiments of the device and system of the present invention will be described with reference to Figures 1 to 58. In these figures, unless otherwise stated, the same reference numerals are used to indicate similar features. When various embodiments are illustrated, the same reference numerals may be used for similar or similar features in subsequent embodiments, but with the addition of multiples of 100, for example, 2, 102, 202, 302, etc.

[0099] The directional terms used in the following description are for illustrative purposes only and are not intended to be limiting. For example, the terms “front,” “back,” “up,” “down,” and other related terms are generally used in reference to the orientation in which the device is illustrated in the drawings.

[0100] Figures 1–26, 31–35, and 49–53 illustrate various embodiments of flexible trusses for a bioabsorbable device to be implanted in a treatment site 62 within a patient's body to drain fluid from or deliver fluid to the treatment site. Trusses 1, 101, 201, 301, 401, and 501 are elastic three-dimensional structures defining elongated channels into which fluid can be drained from or delivered to the treatment site. The trusses are flexible in their longitudinal direction LD, allowing the channels to bend to substantially conform to the contour of the treatment site 62, while at the same time possessing sufficient strength to hold the two tissue surfaces apart without buckling of the truss or collapse or twisting of the channels under clinically appropriate levels of negative pressure, at least at implantation.

[0101] Trusses 1, 101, 201, 301, 401, and 501 are essentially tubular and have a non-circular or circular cross-section. The trusses are configured to provide support to the surrounding tissue surface in all substantially radial directions when in use. The trusses comprises two or more flexible elongated wall members, which are wound in a manner that forms a framework for a channel, thereby defining the channel, into which fluid from the treatment site can be discharged or into which fluid can be delivered to the treatment site. The wall truss members are curved around the channel to follow the curved contour of the inner surface of the channel wall. In many embodiments, the truss wall members have a substantially helical shape.

[0102] The elongated wall members are wound so as to periodically intersect each other at multiple intersection nodes. In a preferred embodiment, the first and second truss wall members are generally helical, but the first wall member has a left-handed winding and the second wall member has a right-handed winding, and they are wound in opposite directions so as to periodically overlap each other. The pitches of the first and second wall members may be the same or different. In an alternative embodiment, the wall members may comprise first and second substantially helical members wound in the same direction but at different pitches, or wall members of an alternative repeating shape, thereby resulting in the first and second wall members having periodic intersection nodes.

[0103] In further alternative embodiments, the first and second wall members may be wound in a non-helical manner such that they generally remain on both sides of the device and engage with each other at intersecting nodes.

[0104] The truss walls and bracing members may be formed from any suitable bioabsorbable filament having sufficient flexibility to allow the device to conform to the contour of the treatment site, and sufficient structural strength and integrity to hold the two surfaces apart, thereby allowing the channel to form. The structural integrity of this material and the resulting shape will also provide a means for the fluid flow channel to be restored if the device is twisted or crushed in any situation. For example, the truss members may include sutures, threads, cords, or tapes of a certain length made from bioabsorbable materials such as polyglycolic acid (PGA), polylactic acid (PLA), polyglycol-polylactic acid copolymer, P4HB (poly-4-hydroxybutyrate), polycaprolactone or polydioxanone, or any mixture thereof.

[0105] For most applications, at least 16mm 2 A channel having a cross-sectional area is desirable. In such embodiments, the wall members may have a pitch length of about 2 mm to about 10 mm.

[0106] The truss further comprises at least two flexible, elongated bracing members, each of which is mechanically connected to two elongated wall members at a plurality of wall member intersection nodes that form periodically interlocked points along the truss. In a preferred embodiment, each bracing member extends substantially longitudinally along the channel wall and along the side of the channel. These bracing members act to maintain the periodic intersection nodes of the wall members in a spaced-out relationship, thereby reducing or preventing collapse of the channel wall due to the relative motion of these points, and preventing crushing and twisting.

[0107] The mechanical connection between the wall members and each bracing member prevents or minimizes relative movement between the wall members and prevents or minimizes movement of each bracing member relative to the intersection node. That is, the intersection nodes of the intersecting wall members cannot slide along the length of each bracing member. The mechanical connection can be formed by each bracing member looping around the wall member at each intersection node, or by the wall members looping around each bracing member at each intersection node. This mechanical interlocking of the bracing members and wall members ensures that the microstructure of the truss at the joint is constant, and therefore the truss at that node is generally not absorbed faster or slower than the rest of the truss structure.

[0108] Bracing truss members are typically provided as a pair of bracing members positioned on either side of the channel. However, alternative embodiments may include additional bracing members, for example, three bracing members generally evenly spaced around the truss tube.

[0109] The truss has a porous structure that allows for free fluid exchange from internal channels to the surrounding area for more effective fluid passage, while using less material than existing solutions. This is advantageous because synthetic bioabsorbable polymers typically release acids when they degrade, which can cause elevated inflammation levels.

[0110] Various embodiments are described below with reference to the drawings.

[0111] Embodiment 1 Figures 1 to 5 show a truss 1 according to the first embodiment. The truss 1 comprises a first wall member 3 having a left-handed, substantially helical shape, and a second wall member 5 wound in the opposite direction and having a right-handed, substantially helical shape. The pitch length P1 of the first wall member 3 is the same as the pitch length of the second wall member 5.

[0112] Truss 1 forms tubes and channels with an oval or elliptical cross-section, having a longer dimension M1 and a shorter dimension N1 less than the longer dimension (Figure 4). The dimension N1 less than M1 can increase the truss's ability to withstand lateral loads compared to a truss with a circular cross-section. The oval or elliptical cross-section can also improve the ease of handling the truss, allowing straight devices to be more easily formed into loop-shaped or "S-shaped" devices when fabricated, and helping to ensure that the truss is accurately oriented when implanted, with the N1 axis holding opposing tissue surfaces apart.

[0113] Two elongated bracing members 7, 9 are provided, extending along the sides of the truss along the shorter axis N1. Referring to the orientation shown, the first bracing member 7 is positioned on the underside of the truss 1, and the second bracing member 9 is positioned on the upper side of the truss. These side bracing members 7, 9 have a length substantially equal to the length of the channel or portion of the channel along which they extend; that is, they are substantially straight members extending along the length of the truss.

[0114] At each intersection node 11, 13 where the first and second wall members 3, 5 intersect, the first and second members are twisted together and extend tightly around their respective bracing members 7 or 9. In the shown embodiment, the first and second members 3, 5 form two complete twists with each other and around their respective bracing members 7 or 9, and are interlocked with the bracing members 7, 9 along distance Y1.

[0115] In one exemplary embodiment having this design, approximately 50 mm 2 For a tube having the cross-sectional area, the wall members 3 and 5 have a half-pitch length x1 of approximately 2 mm, and the length of the interlocked portion y1 formed from the two complete loops of the wall members 3 and 5 is approximately 2.75 mm.

[0116] To reduce the possibility of the intersecting nodes 11 and 13 sliding along their respective bracing members 7 or 9, knots may be provided on the bracing member on either side of each node 11 or 13, for example, at point 8 shown in Figure 1. These knots act to prevent the movement of the twisted portion of the wall member at the node along the bracing member, thereby reducing the possibility of the truss 1 collapsing.

[0117] As will be described in more detail with respect to the following embodiments, the process of manufacturing the truss involves winding a filament around a mandrel. Before removing the truss from the mandrel, the truss is heat-treated to fix its truss shape. The final truss shape is determined by the mandrel shape and fixed by the heat-treatment step.

[0118] Embodiment 101 Figures 6 to 10 show a truss 101 according to a second embodiment. The truss 101 comprises a first wall member 103 having a right-handed, substantially helical shape, and a second wall member 105 wound in the opposite direction, having a left-handed, substantially helical shape. The pitch length P101 of the first wall member 103 is the same as the pitch length of the second wall member 105. The truss 101 forms an oval-shaped tube and channel having a longer dimension M101 and a shorter dimension N101 which is less than the longer dimension (Figure 9).

[0119] In one example, the truss 101 according to this embodiment has a longer dimension M101 of approximately 6.4 mm, a shorter dimension N101 of approximately 3.2 mm, and a pitch length P101 of approximately 4 mm, totaling approximately 16 mm. 2 It has a cross-sectional channel.

[0120] Two elongated bracing members 107 and 109 extend longitudinally along the walls of the truss 101, along the shorter axis N101 on the outside of the wall members 103 and 105. Referring to the orientation shown, the first bracing member 107 is positioned at the bottom of the truss 101, and the second bracing member 109 is positioned on the upper side of the truss 101. These lateral bracing members 107 and 109 have an unwound length that is longer than the length of the channel or portion of the channel along which they extend. The bracing members 107 and 109 are positioned to be located on the outside of the wall members, but in an alternative embodiment, they may be positioned to extend along the inside of the wall members 103 and 105.

[0121] At each intersection node 111, 113 where the first and second wall members 103, 105 intersect, one of the bracing members 107, 109 tightly loops around the intersecting first and second wall members 103, 105, forming a complete 360-degree loop at the node 111, 113. The formed loop is generally located in the vertical longitudinal plane of the truss, coinciding with the shorter axis.

[0122] In the embodiment shown, each bracing member 107, 109 enters each locking loop from the same side (e.g., the left side as illustrated) and exits each loop on the other side (e.g., the right side as illustrated), thereby so that between adjacent intersecting nodes 111 or 113, the bracing members 107, 109 form a slight angle with respect to the longitudinal axis of the truss, as best illustrated in Figure 10. Alternatively, each bracing member 107, 109 may enter each locking loop from one side (e.g., the left side) and exit the loop on the other side (e.g., the right side), and then reverse the direction of the alternating loops, thereby so that between adjacent intersecting nodes 111 or 113, the bracing members 107, 109 are substantially parallel to the longitudinal axis of the truss.

[0123] Figures 11 to 16 illustrate a method for manufacturing the truss 101 shown in Figures 6 to 10. In the first step (Figure 11), the helical first wall member 103 is formed by winding suture filaments or other bioabsorbable polymer filaments around a mandrel. In this embodiment having a non-circular shape, the mandrel may include two cylindrical rods arranged side by side. In one embodiment, the mandrel rods are about 3.2 mm in diameter. The filaments are secured at one end, for example by clamping, and then wound around the mandrel by rotating a filament dispenser around the mandrel while moving linearly, winding the filaments in a helical manner with a first pitch length P101. When the desired length of the truss is reached, the filaments are secured to the mandrel at a second end, for example by locking winding.

[0124] To form the second helical wall member 105, the rotational direction and linear movement speed of the filament dispenser are not changed, but the linear direction is reversed so that the dispenser returns to the first end while the second helical wall member is wound counterclockwise with the same pitch length as the first wall member. The wall member filament is then fixed at the first end and can be cut. The mandrel remains unheated throughout this process so as not to cause thermal bonding between the first and second wall members.

[0125] Referring to Figures 13 to 15, in order to form the first bracing member of the bracing members, in the first step, the filament for the bracing member is fixed to the wall member in the first place, forming a "throw" of filament in front of the fixed end.

[0126] The filament "throw" is passed forward over the nodes where wall members 103 and 105 intersect, and then under and around the nodes before being pulled forward again toward the next node. Once the entire length of the filament throw has been pulled out, and all of the bracing member filament has been pulled out, it forms an interlocking "loop" around the node. Once the loop is formed, tension is applied to the bracing member filament to interlock the bracing member with the wall members. While the loop process is repeated for each node 113 along the upper back of the truss 101, the retaining means keep the bracing member 109 from losing tension. This process is repeated for the bracing member 107 toward the lower nodes 111 of the truss 101.

[0127] Embodiment 201 Figures 17 to 21 show a truss 201 according to a third embodiment. Truss 201 is substantially the same as described above for truss 101 of the second embodiment, except that bracing members 207 and 209 each include sub-filaments 207b and 209b twisted around main bracing member filaments 207a and 209a, respectively. Each sub-filament 207b and 209b is either wrapped around or twisted with the respective main filaments 207a and 209a to reinforce the bracing members, improve the buckling resistance of the bracing members, and prevent movement of the interlocking loops 211 and 213 along the bracing members.

[0128] In the embodiment shown, the bracing member secondary filaments 207b, 209b wrap around each main member 207a, 209a for one complete loop between adjacent interlocking nodes 211, 213 and pass through the interlocking loop at the nodes 211, 213 outside the joint. In this embodiment, the secondary filaments do not directly interlock with the wall members 203, 205. The secondary filaments 207b, 209b can help prevent movement of the interlocking loop within each main bracing member filament 207a, 209a.

[0129] As best illustrated in Figure 19, the windings of the bracing member sub-filaments 207b and 209b have a consistent rotational direction and winding motion around their respective main members 207a and 209a, but wind at a varying winding angle. When the sub-filaments pass over the interlocking loops, the winding angle tends to be shallower and the winding length longer, but when the sub-filaments are wound around the main filaments of the bracing member between nodes, the angle becomes steeper.

[0130] In some embodiments, the first and second auxiliary filaments 277b and 209b are wound in opposite directions. This opposite winding direction may help prevent twisting of the manufactured truss when it is removed from the mandrel.

[0131] Embodiment 301 Figures 22 to 26 show a truss 301 according to a fourth embodiment. Similar to the embodiments described above, the truss 301 comprises a first wall member 303 having a left-handed, substantially helical shape, and a second wall member 305 wound in the opposite direction having a right-handed, substantially helical shape. The pitch length P301 of the first wall member 303 is the same as the pitch length of the second wall member 305. The truss 301 forms an oval-shaped tube and channel having a longer dimension M301 and a shorter dimension N301 which is less than the longer dimension (Figure 25).

[0132] The truss 301 has two elongated bracing members 307, 309 that extend longitudinally along the walls of the truss 301, on the upper and lower sides along the shorter axis N301. Each bracing member comprises two filaments 307a, 307b, 309a, 309b twisted together, and the wall members 303, 305 are captured and held between the two filaments of their respective bracing members at their respective wall member intersection nodes 211, 213.

[0133] In the shown embodiment, the bracing member filaments 207a, 207b, 209a, and 209b form two complete twists along the pitch length of the wall member, but in an alternative embodiment, there may be more or fewer twists depending on the thickness of the bracing member filaments and the pitch length P301 of the wall member. The pitch length P301 is determined by the number of twists between nodes 311 and 313.

[0134] In some embodiments, the filaments 307a and 307b of the first bracing member 307 are twisted in the opposite direction to the filaments 309a and 309b of the second bracing member 309. This opposite winding of the top and bottom bracing members may help prevent twisting of the manufactured truss when the manufactured truss 301 is removed from the mandrel.

[0135] Embodiment 401 Figures 31 to 35 show a truss 401 according to a fifth embodiment. Truss 401 is substantially the same as described above for truss 1 of the first embodiment, in which first and second wall members 403, 405 are wound around bracing members 407, 409 at nodes 411, 413. However, in this embodiment, the wall members are not helical. The first wall member is the right-side wall member, and the second wall member is the left-side wall member.

[0136] The first and second wall members 403, 405 are wrapped such that they generally remain on the same side of the bracing member along the length of the truss. At each node 411, 413, each wall member 403, 405 loops around each bracing member 407, 409 one and a half times and exits the node on the same side it entered the node. This is best illustrated in Figures 33 and 34, where the length of the second wall member 405 is shaded to illustrate the nature of the wrap. The number of loops of each wall member 403, 405 around each bracing member 407, 409 is at least one but may vary between embodiments; in the embodiments shown, the wall members are wrapped around the bracing member 540 degrees (i.e., one and a half turns). In other embodiments, the wall members may be wrapped around the bracing member 720 degrees (i.e., two or more turns).

[0137] Referring to the plan view in Figure 33, the subsequent "winding" of each wall member 403, 405 extending between the first bracing member 407 and the second bracing member 409 may overlap with or come into contact with the existing winding of the wall member at the contact point 406. This contact point 406 will generally occur approximately midway between the first bracing member 407 and the second bracing member 409, but it may occur at other locations.

[0138] Figures 33 and 34 also show that the winding direction of the wall members 403 and 405 around the first bracing member 407 is opposite to the winding direction of the wall members 403 and 405 around the second bracing member 409. This opposite winding direction may help prevent twisting of the manufactured truss 401 when it is removed from the mandrel after manufacturing.

[0139] Figures 36(i) to 39(iv) illustrate the formation of the truss 401 in this embodiment. In the first step shown in Figures 36(i) to 36(iv), the first and second wall members 405 and 407 are twisted around the top bracing member 409 for 1.5 loops to form the first node 413a.

[0140] In the second and third steps shown in Figures 37(i) to 38(iv), the first and second wall members 405 and 407 are then pulled down relative to the lower bracing member 407 to a point almost directly below their exit from the first node 413a before being twisted together around the lower bracing member 407 at a new node 411. The wall members 403 and 405 are twisted in the opposite direction to the twisting around the upper bracing member 409.

[0141] As best shown in Figure 38(iii), the first wall member 403 exits the first node 413a at the bottom of the top bracing member 409 and enters the next node 411 on the lower bracing member 407 from the bottom of the lower bracing member 407. Conversely, the second wall member 405 exits the first node 413a at the top of the top bracing member 409 and enters the next node 411 on the lower bracing member 407 from the top of the lower bracing member 407.

[0142] In the fourth step, the first wall members 403 and the second wall members 405 are then pulled up again relative to the top bracing member 409 to a point almost directly above their exits from an existing node 411. The wall members 403 and 405 are twisted together around the top bracing member 409 at a new node 413b in the opposite direction to the twisting around the lower bracing member 407. As the wall members traverse from the lower bracing member 407 to the top bracing member 409, they may overlap and / or contact each other.

[0143] Figures 40 to 43 illustrate a handheld device 471 for use in manufacturing a truss 401 of a fifth embodiment. The device may also be used to manufacture other embodiments having two twisted wall members, for example, trusses 1 and 501 of Figures 1 to 5 and 49 to 53, respectively. The device 471 comprises a body 485, a handle 481, retractable latches 479 and 483, and first and second filament bobbins 473 and 487. The bobbins 473 and 487 are rotatably held on both sides of the body 485 on their respective shafts 475 and 491 and are biased to contact the body 485 by springs 477 and 488. Springs 477 and 489 act between the heads of their respective shafts 475 and 491 and the ends of the bobbins 473 and 487.

[0144] The bases of each bobbin 473, 487 are provided with ratchet surfaces 474, 488. Each latch 479, 483 extends from the body to engage with the ratchet surface of each bobbin. The latches 479, 483 extend through the body 485 to engage with the ratchet surface and selectively retract from engagement with the ratchet surface, allowing the bobbin 487 to rotate freely, for example, by retracting into the body 485 when the handle 481 is rotated around its longitudinal axis. The filament from each bobbin extends through the respective guide openings 493 provided at the front of the body of the device.

[0145] Figures 44A to 48C illustrate a method for manufacturing a truss 401 of a fifth embodiment using apparatus 471. In the first step, the top and bottom filaments 407 and 409 are fixed and tensioned along the apparatus on either side of the mandrel 495 in the tension direction T to form the first and second bracing members. The mandrel 495 is a double mandrel formed from two parallel cylindrical rods.

[0146] When the handle 481 is rotated to "free" the bobbins 473 and 487, the first and second filaments from the bobbins 473 and 487 then rotate freely to feed out the filaments and form the wall members 403 and 405. Once sufficient filaments have been fed out, the handle 481 is rotated to engage the latches 479 and 483 with the bobbin ratchet surface, allowing tension to be applied. First, the first and second filaments are twisted in a vertical line around one of the bracing members (the top bracing member 409 in Figure 44B) for one and a half loops by rotating the device 471 around an axis parallel to the respective bracing members 409. Then, by operating the device 471, the two filaments are separated and positioned on either side of the mandrel 495, preparing to be connected to the lower bracing member 407. With the device 471 positioned beneath the tensioned lower bracing member 407, the handle 481 is rotated in the opposite direction to the first step, twisting the first and second filaments in a longitudinal line around the other bracing member (the lower bracing member 407 in Figures 47A and 47B) to complete the first "winding" of the truss 401. Throughout this fabrication process, the tool 471 generally follows a planetary orbit around the longitudinal axis of the mandrel, with the underside of the device 471 facing the mandrel and maintaining a consistent orientation of the filaments.

[0147] Next, the twisted loops are pushed along the lower bracing member 407 until they partially lie beneath existing loops on the upper bracing member 409 and / or abut against existing windings on the lower bracing member 407, allowing the filaments to exit the bobbins 473, 487. The bobbins 473, 487 are then locked against the apparatus body 485 by engaging latches 479, 483 with the bases 474, 484 of the respective bobbins, and the process is repeated. Apparatus 471 is operated to separate the filaments on the mandrel 495 before the filaments are twisted again around the upper bracing member 409 to form a second "winding" of the truss 401. Means are provided to prevent tension loss in any formed truss structure on the mandrel while the filaments are being fed out.

[0148] The illustrated process utilizes a handheld device 471, but this process may be automated.

[0149] Embodiment 501 Figures 49 to 53 show a truss 501 according to the sixth embodiment. The truss 501 is substantially the same as the truss 401 of the fifth embodiment described above, but comprises two first wall members 503a and 503b and two second wall members 505a and 505b.

[0150] This embodiment can be manufactured in a manner similar to the process described above, but utilizes two handheld manufacturing devices. The first device 471 has a bobbin for holding one first wall member 503a and one second wall member 505a, and the second device 471 has a bobbin for holding the other first wall member 503b and the other second wall member 505b. The two devices operate simultaneously, twisting the wall members at the same time around the first and second bracing members 507, 509.

[0151] The opposing wall members 503a and 505a, and 503b and 505b, overlap at the point between the upper reinforcing member 507 and the lower reinforcing member 509. This overlap occurs during manufacturing when the device 471 is moved from one reinforcing member 509 to the other reinforcing member 507.

[0152] Embodiment 601 Figures 54–58 show a truss 601 according to the seventh embodiment. Truss 601 is substantially the same as that described above for truss 401 of the fifth embodiment, except that at each node 611, 613, truss members 603, 605 wrap around their respective wall members 607, 609 for two complete loops (in contrast to the one and a half loops of embodiment 401). In some of the figures, shading is used to visually distinguish the first truss member 603 from the second truss member 605.

[0153] Each of the first and second truss members 603 and 605 alternates between being on the left side of the wall members 607 and 609 and being on the right side of the wall members (in contrast to remaining on one side of the wall members 607 and 609 in embodiment 401). This can result in a more robust truss structure.

[0154] In this embodiment, the twisted portions of the truss members 603 and 605 cover substantially the entire length of each wall member 607 and 609. There are substantially no exposed wall members between adjacent first nodes 611 or adjacent second nodes 613.

[0155] This embodiment 601 may be manufactured in a manner similar to the process described above in relation to 401, but the truss members are twisted around the wall members for two full rotations at each node.

[0156] device The trusses described above may be used as structures in bioabsorbable devices, such as those described in PCT international application PCT / NZ2018 / 050134, which is fully incorporated herein by reference.

[0157] Such a device may comprise a flexible bioabsorbable sheet that forms at least partially the channel wall. In some embodiments, the flexible sheet may only partially form the channel wall, with the remaining portion of the channel wall being formed by the tissue surface when the device is in use. That is, the channel may be formed between the surface of the flexible sheet and the surface of the tissue or bone at the treatment site. Alternatively, the flexible sheet may form the main part or substantially the entirety of the channel wall. Such embodiments may comprise two or more bioabsorbable flexible sheets having a truss that holds the sheets apart so that one or more channels are defined between the opposing surfaces of the sheets, or a single flexible bioabsorbable sheet may be wrapped around the truss to form the channel wall.

[0158] To secure the flexible sheet to the truss or around it, the sheets may be sewn together along the seams on the sides of the channel, or joined in other ways. To facilitate fluid flow into the channel, openings may be provided in the sheet, and the distribution, size, and shape of the openings are selected according to the application and characteristics of the flexible sheet and the truss.

[0159] In some embodiments of the present invention, the flexible sheet is formed from ECM. ECM sheets are typically collagen-based biodegradable sheets containing highly conserved collagen, glycoproteins, proteoglycans, and glycosaminoglycans in their natural composition and concentrations. ECM can be obtained from a variety of sources, such as dermal pericardium or intestinal tissue taken from animals raised for meat production, including pigs, cattle, and sheep, or other warm-blooded vertebrates.

[0160] The ECM tissue suitable for use in this invention contains naturally bound ECM proteins, glycoproteins, and other factors naturally found within the ECM depending on the source of the ECM. One source of ECM tissue is the foregum tissue of warm-blooded vertebrates. The ECM suitable for use in this invention may be in the form of a mesh or sponge sheet.

[0161] Foregum tissue is a preferred source of ECM tissue for use in the present invention. Preferred foregum ECM typically includes the lamina propria-submucosa of the foregum of ruminants. In specific embodiments of the present invention, the lamina propria-submucosa is from the rumen, tarum, or tertiary stomach of the foregum. These tissue scaffolds typically have a contoured luminal surface. In one embodiment, the ECM tissue contains decellularized tissue including epithelium, basement membrane, or a portion of the gastric myometrium, and combinations thereof. The tissue may also contain one or more fibrous proteins, including but not limited to collagen I, collagen III, or elastin, and combinations thereof. These sheets are known to vary in thickness and definition depending on the source of the vertebrate species.

[0162] A method for preparing ECM tissue for use according to the present invention is described in U.S. Patent No. 8,415,159.

[0163] In some embodiments of the present invention, sheets of polymer material may be used. The polymer material may be in the form of a sheet or a mesh. Synthetic materials such as polyglycolic acid, polylactic acid, and polyglecapron-25 will provide additional strength in the short term but will be reabsorbed in the long term. Alternatively, the polymer material may be a natural material or may be derived from natural materials such as proteins (e.g., collagen), polysaccharides (e.g., alginates), and glycoproteins (e.g., fibronectin).

[0164] Any desired bioactive molecule can be incorporated into the ECM or polymer material or the truss member material itself. Suitable molecules include, for example, small molecules, peptides or proteins, or mixtures thereof. The bioactive material may be endogenous to the ECM or may be a material incorporated into the ECM and / or polymer material during or after the graft manufacturing process. In some embodiments, two or more distinct bioactive molecules may be incorporated non-covalently into the ECM or polymer. The bioactive molecule may be incorporated non-covalently into the material as a suspension, encapsulated particles, microparticles and / or colloids, or mixtures thereof. The bioactive molecule may be distributed between layers of the ECM / polymer material. Examples of bioactive materials, but not limited to, include proteins, growth factors, antimicrobial agents, and anti-inflammatory agents including doxycycline, tetracycline, silver, FGF-2, TGF-B, TGF-B2, BMR7, BMP-12, PDGF, IGF, collagen, elastin, fibronectin, and hyaluronan. In some embodiments, the truss members may be coated with one or more drugs or compounds, for example, for elution. One example is the use of chlorhexidine coating as an antimicrobial agent to prevent biofilm formation.

[0165] Fabricating truss structures that do not rely on the use of head bonding to join truss members can also advantageously help preserve the integrity of any antimicrobial coatings on the truss filaments. In contrast, these coatings may be affected in structures that rely on the thermal bonding of truss members.

[0166] Truss 1 may define a single channel or multiple interconnected channels, for example, as a branched structure. While some devices of the present invention will have many channels for fluid flow, it will be understood that some devices of the present invention may have only one or two channels.

[0167] The device has ports that communicate fluids with the device's channels, so that any fluid discharged into any one of the channels flows toward and out of the ports. The ports may be configured for locations inside the patient, or for external locations, such as on the outer surface of the patient's skin, or separately, for locations outside the patient's body near internal surgical openings. The ports may consist only of openings at the ends of the truss or channels to communicate with conduits from negative or positive pressure sources.

[0168] The port may have features to enhance the coupling between the conduit and the device. For example, the shape, diameter, and / or structure of the device truss may vary adjacent to the port. The truss may be coupled to the inlet or outlet conduit by internal or external coupling. The truss may include a length adjacent to the port having an increased diameter or modified characteristics to form a releasable connection with the supply conduit or lumen. The truss pitch may vary in this region to ensure that the connection has appropriate mechanical properties, such as the required increase in strength and stiffness. This change in pitch and diameter preferably occurs gradually across the transition region.

[0169] Figures 27–30 illustrate one method of connecting an exemplary truss 301 to an inlet lumen 271 and an outlet lumen 272 of a dual-lumen conduit 270 for use in a wound healing system. In this embodiment, the inlet and outlet conduits are provided by a dual-lumen conduit 270 having a larger lumen and a smaller lumen, as also illustrated in Figures 59(i) and 59(ii). The dual-lumen conduit is divided along the length of the conduit 270 adjacent to the connection with the truss into a supply conduit 271 having the smaller lumen and an outlet conduit 272 containing the larger lumen.

[0170] The supply conduit 271 is connected to the first end of the truss 301 by inserting the supply conduit 271 into the truss 301, as illustrated in Figures 27 and 30. The outlet conduit 272 is connected to the other end of the truss 301 using a connector 273. The connector 273 is a molded component that forms an internal push-fit connection with the outlet conduit 272 and slides on the outside of the truss 301, as illustrated in Figure 29. The connector 273 has a tapered outer surface for engaging with the inner surface of the conduit 272 to ensure a firm mating between the two components. The firm mating is important to ensure that the connector 273 is removed together with the conduit 270 / 272 when treatment is complete.

[0171] The inlet and outlet ports of the truss 301 are separated to ensure that the fluid supplied by the supply lumen 271 does not flow directly between the lumens to the outlet lumen 272, but is instead supplied to the wound.

[0172] It will be understood that other methods of connecting the device to the supply conduit, including additional retaining features, are understood and assumed. For example, the outer surface of the conduit may be threaded or have projections / retractors for additional engagement with the truss to prevent unintended disconnection, or the connector for connecting the conduit to the truss may have retractors, bars, threads, or other features for engaging with the truss and / or the conduit. In one embodiment, a barbed feature is provided on the tapered section of the connector 273 to interface with the connector in order to increase the force required to separate the connector from the truss and / or the removal conduit 272.

[0173] The devices described herein can, advantageously, be customized to adjust the duration of time the device functions in situ within a living organism for any given application. This can be done, for example, by adjusting the channel size, wall thickness, or thickness or density of the truss members, or the number and type of bracing members.

[0174] System and method for use Figures 60–63 illustrate the placement and use of a bioabsorbable device 61, comprising the truss 1 described above, implanted in a treatment site 62 within a patient's body for the purpose of draining fluid from or delivering fluid to the treatment site. The treatment site 62 may be a space between the surfaces of muscle tissue 63, adipose tissue 64, or skin tissue separated during surgery or as a result of trauma. The treatment site may also be a dead space 65 resulting from an excised seroma or hematoma, or may be used as prophylaxis after surgical excision of tissue. Alternatively, the treatment site may be an open wound, such as after trauma, injury, or surgical excision of necrotic or infected tissue, with an occlusive drape or cover placed over the wound to create a sealed environment. The system is illustrated with the truss 1 of the first embodiment, but trusses 1, 101, 201, 301 of any embodiment described above may be substituted.

[0175] The bioabsorbable device 61 is used as part of a system for draining fluid from or delivering fluid to a treatment site 62. The bioabsorbable elastic truss 1 of the device holds two tissue surfaces 63, 64 apart, thereby defining a channel 66 into which fluid can be drained from the treatment site, or from which fluid can be delivered to the treatment site. The two tissue surfaces 63, 64 must be held apart because they would otherwise collapse together, especially under the application of negative or reduced pressure (vacuum) to aid in fluid drainage.

[0176] The port 71 or opening at one end of the truss 1 in that configuration is in fluid communication with the channel 15, enabling connection of the channel to a negative or positive pressure source 73 and providing fluid communication between the treatment site 62 and the port 71 of the device 61. The conduit 14 is releasably coupled to either the port 71 of the device 61 or a fluid-impermeable covering so that it is in fluid communication with the device 61. In the illustrated use of the device, the port 71 is located inside the body, and the inlet and outlet conduits pass through the skin. This configuration is desirable because the body creates a seal around the connection of the conduit to the port.

[0177] In an alternative embodiment, the port 71 may be coupled to an impermeable covering located on the outer surface of the patient's skin 106, providing an airtight seal around the skin incision and an alternative means by which the conduit is releasably coupled to the covering.

[0178] A reservoir (described further below) is located outside the patient's body and is fluid-communicated with the conduit to receive fluid from the conduit or to hold therapeutic fluid for delivery of fluid to the conduit 14. The pressure source 73 may deliver negative pressure to the device 61 so that fluid is discharged from the treatment site 62 into the device 61 and transferred to the reservoir through the conduit 14, or it may deliver positive pressure to the device so that fluid in the reservoir is transferred through the conduit into the device and to the treatment site. In a preferred embodiment, the therapeutic fluid is delivered to the wound by applying vacuum pressure downstream of the device while the fluid is supplied to the device from an ambient pressure upstream source.

[0179] The pressure source 73 is typically a vacuum pump for applying negative pressure to drain fluid from the treatment site and / or draw therapeutic fluid from the treatment site; alternatively, the pressure source may be a pump for pumping fluid from the reservoir into the device 61 for delivery to the treatment site. The pump may be operated manually, for example, using a squeeze valve, or it may be electronically controlled for more precise delivery of fluid to the site.

[0180] Figures 64–68 show exemplary embodiments of negative pressure treatment systems 2100, 2200, and 2300 (referred to as treatment systems herein) for removing fluid from a wound treatment site 62, or for supplying treatment fluid to a wound treatment site 62 and removing the fluid therefrom, using a wound treatment device 61. The wound treatment device 61 of the system may be any one of the devices described herein.

[0181] In relation to the exemplary embodiment systems 2100, 2200, and 2300, similar reference numerals are used for different embodiments to indicate similar features.

[0182] Referring to Figure 64, at a general level, the treatment system 2100 comprises a wound treatment device 61 located at the wound treatment site 62 ("wound"), a vacuum pressure unit 2002 including a vacuum pump assembly for applying negative pressure to the wound 62 via the treatment device 61, and a fluid collection reservoir 2006 for collecting fluid returned from the wound 62. Figure 65 illustrates an internal wound site located in the patient's chest, but the system can be used to treat internal wounds located in other areas, for example, to treat abdominal wounds.

[0183] The vacuum pressure unit (or vacuum unit) 2002 is configured to position the pump assembly 2015 upstream of the fluid collection reservoir 2006 and downstream of the wound treatment device 61. The wound treatment device 61 may include a locally applied wound dressing, an implanted treatment device, or a combination of both in a combined configuration. The fluid collection reservoir 2006 is configured to include one or more air-permeable filters or vents 2006a to maintain the fluid collection reservoir 2006 and the connected conduit 2005c at ambient pressure levels.

[0184] The vacuum unit 2002 is fluid-coupled to the wound healing device 61 via at least one conduit. The conduit from the vacuum unit 2002 to the wound healing device 61 may comprise a two-part conduit having a first conduit 2005b extending from the vacuum unit 2002 and a second conduit 2005a extending from the wound healing device 61. The second conduit may be part of the wound healing device 61 or may be connected to the healing device 61 by a connector (not shown). A connector 2007 is provided for fluid-coupled the first conduit 2005a and the second conduit 2005b. Alternatively, a continuous conduit may extend between the vacuum unit 2002 and the healing device 61.

[0185] The connector 2007 may include a one-way valve oriented to allow fluid flow from the wound 62 toward the vacuum unit 2002 and to prevent backflow of fluid from the pump toward the wound. In an alternative embodiment, the one-way valve may instead be provided within the vacuum unit 2002, elsewhere on the conduits 2005a, 2005b, or as part of the treatment device 61. In a further alternative example, the treatment system 2100 may not have a one-way valve between the treatment device 61 and the vacuum unit.

[0186] In some embodiments, the conduit between the vacuum unit 2002 and the treatment device 61 may comprise a dual-lumen conduit with a main lumen and a secondary lumen for the passage of fluid flowing from the wound to the pump assembly 2015. The secondary lumen may allow for the measurement of pressure at the wound site. The secondary lumen provides for the delivery of air and / or treatment fluid to the wound 62. However, in alternative embodiments, multiple conduits may be provided between the vacuum unit 2002 and the treatment device 61, each with a single lumen.

[0187] To fluid-couple the pump assembly 2015 to the reservoir 2006, an additional conduit 2005c is provided between the vacuum unit 2002 and the reservoir 2006. A connector 2008 may be provided to fluid-couple the conduit 2005c to the reservoir 2006.

[0188] In a preferred embodiment, the vacuum unit 2002 is a portable handheld unit. The vacuum unit 2002 may be a single-use unit intended for use on one patient. In an alternative embodiment, the vacuum unit 2002 may be configured for use on multiple patients. The vacuum unit 2002 comprises a (plastic) shell or housing for housing the pump assembly 2015 and other components. The vacuum unit 2002 comprises a user interface 2014 for operating the vacuum unit 2002. The user interface may include controls for turning the pump assembly 2015 of the system 2100 on and off, and may allow the operator to control parameters of pressure therapy applied to the wound 62, such as the level of vacuum pressure being applied, or the length, size, and frequency of pressure oscillations between an upper and lower setpoint.

[0189] In an alternative embodiment, the user interface 2014 may also include controls to remotely connect a monitoring device to the vacuum unit, enabling the transmission of data to a system operator or user, thereby assisting in the monitoring of treatment.

[0190] Referring here to Figure 66 in conjunction with Figure 64, the vacuum unit 2002 comprises a housing or enclosure that accommodates a vacuum pump assembly 2015, which will be described in more detail below, a battery or other power source, a vacuum unit connector 2009 which is in fluid communication with conduits 2005b, 2005a for delivering and receiving fluid from the wound healing site 62, and a vacuum unit outlet connector 2010 which is in fluid communication with conduit 2005c to the reservoir 2006 for fluid flow from the pump assembly 2015 to the reservoir 2006. The connectors 2009, 2010 are configured to couple with the ends of their respective conduits 2005b, 5c and may be in any preferred form, for example, they may include Luer-type connectors.

[0191] In one embodiment, the vacuum unit connector 2009 may comprise two one-way valves such that the one-way valves in the sub-connector 2009b are oriented to allow fluid flow to the wound 62 from an upstream source such as ambient air that has passed through a sterilization filter (filter 2019 in Figures 68 and 69) or from a therapeutic fluid reservoir (reservoir 2026 in Figures 68 and 69). The corresponding one-way valves in the main connector 2009a are oriented to allow fluid flow from the wound 62 toward the vacuum unit 2002. In some embodiments, the one-way valves in the main connector 2009a and the sub-connector 2009b may be configured to close when the vacuum unit connector 2009 is disconnected from the vacuum unit 2002. These valves are then opened to allow fluid passage when the connected vacuum unit 2009 is reconnected to the vacuum unit 2002. Known prior art connectors possessing such characteristics include needleless or needle-free connectors for use in IV applications, such as BD® MaxPlus® needleless connectors, which, when engaged with a suitable Luer locking connector, only allow the passage of fluid.

[0192] The conduit 2005b for fluid flow in and out of the vacuum unit connector 2009 is a dual-lumen conduit with a main lumen 2011 and a secondary lumen 2012. The connector 2009 includes a main connector 2009a providing a fluid inlet for connection to the main lumen 2011 and a secondary connector 2009b providing a fluid outlet for connection to the secondary lumen 2012, leaving the flow from these lumens isolated. The larger main lumen 2011 allows the passage of fluid flowing from the wound through the main connector to the vacuum pump assembly 2015. The secondary connector or supply connector 2009b may be separated from the main connector or removal connector 2009a.

[0193] The main lumen 2011 and the secondary lumen 2012 are preferably provided as adjacent passages within a single body / conduit along most of their length. However, adjacent to the vacuum unit 2002 and / or adjacent to the wound treatment device 61, dual-lumen conduits 2005a, 2005b may be divided or separated into two separate branches or conduits: a supply conduit with a secondary lumen 2012 and a removal or exudate conduit with a main lumen 2011, for ease of connection to the vacuum unit 2002 and / or to allow the supply conduit to enter the wound or wound treatment device 61 at a different location from the removal conduit. The main or removal conduit and lumen may be interchangeably referred to by reference number 2011, and the secondary or supply conduit and lumen may be interchangeably referred to by reference number 2012.

[0194] The supply conduit 2012 is in fluid communication with the pressure sensor Pv, enabling the measurement of the pressure upstream of the wound healing device 61.

[0195] The vacuum unit 2002 includes an air inlet valve 2018 that is in fluid communication with the supply conduit 2012. The air inlet valve 18 is controlled in such a manner that it introduces air into the treatment system 2100 to assist in lifting the fluid from the wound site 62, as will be described in more detail below.

[0196] As shown in Figure 66, the air inlet valve 2018 may have an inlet for drawing ambient air into the system from outside the vacuum unit 2002 housing. Alternatively, the inlet of the air inlet valve may draw air from inside the vacuum unit housing / enclosure.

[0197] A sterilization filter 2019 is provided to prevent biological contamination and non-sterile air from entering the system 2100 and the wound site 62. In Figure 66, the filter 2019 is provided at the inlet of the air inlet valve 2018, but the filter may be located elsewhere between the air inlet valve 2018 and the vacuum unit fluid supply connector 2009b, or between the air inlet valve 2018 and the wound site 62.

[0198] Figure 67 illustrates the treatment system 2100 in more detail. The boundary or outer housing of the vacuum unit 2002 is illustrated by dashed lines in Figure 67. Upstream of the treatment device 61, the vacuum unit 2002 comprises an air inlet valve 2018, optionally a pressure sensor Pv and a sterilization filter 2019, and downstream of the treatment device 61, the vacuum unit 2002 comprises a pump assembly 2015 and optionally a pressure sensor Pp between the pump assembly 2015 and the treatment device 61. The vacuum unit 2002 may also comprise a connection manifold 2020 that provides a connection interface between the conduits 2005a, 2005b to the treatment device 61 and the vacuum unit 2002. The connection manifold 2020 is illustrated by dotted lines in Figure 67 and replaces the connector 2009 shown in Figure 66.

[0199] In the system 2300 of the embodiment shown in Figure 69, the vacuum unit 2002 additionally includes a color sensor 2024 electronically connected to the vacuum unit controller 2017. In this embodiment 2300, the color sensor 2024 is positioned along a fluid path located between the outlet of the pump 2015 and the outlet connector 2010. However, the color sensor may alternatively be positioned along the fluid path at any preferred location upstream of the inlet of the pump 2015.

[0200] The color sensor 2024 may be useful for detecting color changes in wound exudate flowing from the treatment device 2003 through the system at the wound site 2004. For example, the natural color change from the initial blood-rich wound exudate immediately after surgery to the pink color of serous blood-like drainage (blood and serum) and / or clear serous drainage (serum only). This operation of the color sensor 2024 can be enhanced by supplying filtered air from upstream of the treatment device 2003. The filtered air displaces the fluid for a short time frame, similar to the case of direct aspiration of fluid from the treatment site 2004 via a needle, generating a readable sample of the fluid within that short time frame.

[0201] Inclusion of a color sensor within the system of various embodiments for supplying and removing therapeutic fluid from a wound may offer further advantages. For example, the color sensor 2024 may be configured to detect the passage of therapeutic fluid supplied from the therapeutic fluid reservoir 2026, through the upstream fluid path, the removal conduit 2011, the wound healing device 3, and the supply conduit 2012, to the vacuum unit 2002, and to indicate complete saturation of the therapeutic fluid through the connected system. In other embodiments, the therapeutic fluid may be combined with a color-based indicator for detecting changes in the wound in response to the presence of infection, biofilm, or other wound-based lesions.

[0202] Figures 68 and 69 illustrate further embodiments of treatment systems 2200, 2300 for supplying fluid to a wound and removing fluid from a wound. The embodiments of Figures 68 and 69 include the same or similar features as the system 2100 described above with reference to Figures 64 to 67, but are additionally configured to provide a treatment fluid to the wound treatment device 61.

[0203] Referring to Figures 68 and 69, the vacuum unit 2002 may have one or more ports 2025 for receiving therapeutic fluid for delivery to the wound site. The ports 2025 are preferably configured to nominally close to the fluid passage when disconnected from the therapeutic fluid reservoir 2026, and then open when engaged with a Luer connector. B. Braun Medical® CARESITE® unnecessary connectors provide an example of such ports.

[0204] Therapeutic agents in the form of therapeutic fluids can be selectively delivered to the wound healing device 61 via the supply conduit 2012. The fluid source or therapeutic fluid reservoir 2026 can be coupled to the fluid port 2025 of the vacuum unit 2002 via a conduit or connection to an intravenous (IV) fluid administration set, such as, for example, the Baxter® EMC 9608 Admin Set, the B. Braun Medical® Single Chamber IV Infusion Set, or a similar sterile IV infusion therapy set. The therapeutic fluid reservoir is preferably at atmospheric pressure while connected to the therapeutic system. This can be achieved by using a non-permeable IV infusion therapy set in combination with a flexible fluid bag, such as the Baxter® Sodium Lactate (Hartmann or Composite Sodium Lactate) IV Bag, or by connecting a permeable IV infusion therapy set to a rigid or semi-rigid container of therapeutic fluid, such as the Prontosan® Wound Irrigation Solution by B. Braun Medical®.

[0205] Examples of therapeutic fluids include, but are not limited to, sodium lactate compounds, physiological saline (0.9% NaCl - sodium chloride), and 0.45% physiological saline (0.45NaCl). Antimicrobial agents and solutions may also be applied to the treatment of infections and may contain agents such as polyhexanide (PHMB), silver nitrate, hypochlorous acid (HOCl), sodium hypochlorite, betaine, sodium hypochlorite, superoxidized water at neutral pH, or any other antimicrobial wound irrigation solution.

[0206] Other therapeutic fluids may also include cell suspensions and cell-based fluids for promoting wound healing. The delivered fluid may contain one or more nutrients, a “fluid fluid” such as a thixotropic gel or a highly viscous fluid that can still be transported via a conduit, and a cell suspension therapeutic agent for promoting wound healing. Fluids may include, for example, fluid gels derived from ECM, hyaluronic acid, growth factors to aid healing, antimicrobial agents for treating infections, analgesics such as fentanyl or morphine for pain relief, and anti-inflammatory agents such as ketorolac or diclofenac, but other fluids are conceivable and will be apparent to those skilled in the art.

[0207] Infusions of autologous or allogeneic cell-based therapies containing platelet-rich plasma, stem cells, stromal cells, keratinocytes, lymphocytes, bone marrow aspirate, serum, and dendritic cells may aid in wound repair and healing. Infusions of chemotherapeutic agents may also aid in the local treatment of cancerous cells that may not be surgically treatable, or they may be used as part of an overall treatment plan after the resection of cancerous tissue.

[0208] Referring to Embodiment 2200 in Figure 68, the therapeutic fluid inlet valve 2022 is selectively operable to allow fluid to flow from the therapeutic fluid reservoir 2026 into the supply conduit 2012 leading to the wound. The fluid reservoir is at atmospheric pressure. When the therapeutic fluid inlet valve 2022 is selectively opened, the negative pressure from the pump assembly 2015 applied to the wound 62 via the removal conduit 2011 acts to draw fluid from the therapeutic fluid reservoir 2026 toward the dressing or wound healing device 61. Upon activation of the therapeutic fluid inlet valve 2022, a controller in the vacuum unit 2002 (not shown in this figure) detects a subsequent drop in the vacuum pressure level in the Pv and / or Pp pressure sensors and activates the pump assembly 2015 to maintain the vacuum pressure at a target level. The control algorithm is described in more detail below. In the exemplary embodiment, an air inlet valve 2018 and a sterile filter 2019 are provided upstream of the therapeutic fluid valve 2022.

[0209] In Embodiment 2300 of Figure 69, the system does not have a therapeutic fluid inlet valve 2022. System 2300 may include an orifice or other flow limiter to control the amount of therapeutic fluid introduced into the system during negative pressure therapy. In one embodiment, the administration of therapeutic fluid is controlled via the use of an intravenous (IV) fluid administration set, such as a Baxter® EMC 9608 Admin Set, a B. Braun Medical® Single Chamber IV Infusion Set, or a similar sterile IV infusion therapy set, connected to unit 2002 via a fluid port 2025. The fluid flow rate of the therapeutic fluid introduced into the supply conduit 2012 is controlled via a roller clamp in the set, which is adjusted to change the flow limit in a section of the tube interface with the roller clamp component. In this embodiment, the fluid drip rate may be visually checked via the drip chamber of the IV infusion set when the chamber is oriented upright, and any further flow adjustments are made via roller clamp adjustment. This embodiment provides a manual means for introducing a therapeutic fluid into a wound 62 via a wound treatment device 61.

[0210] In an alternative embodiment, the vacuum unit 2002 may be connected to an infusion pump via a fluid port 2025 to allow fluid to be supplied to the wound healing device 61 in a selectable and controllable manner. Such an infusion pump system may include, for example, a B. Braun Medical® Vista® basic high-capacity infusion pump or a BD® Alaris® Syringe Module, which can controllably deliver therapeutic fluid at a rate of 0.1 ml / hour to 1200 ml / hour, either intermittently or on a constant fluid delivery basis. These systems typically propose means for selecting the volume, flow rate, and frequency at which the therapeutic fluid is dispensed. When the therapeutic fluid is introduced into the vacuum unit 2, the system detects a subsequent drop in the set vacuum pressure level using Pv and / or Pp pressure sensors and activates the pump assembly 2015 to maintain the system target level of vacuum pressure. The control algorithm is described in more detail below.

[0211] In the embodiments shown in Figures 68 and 69, the vacuum unit 2 includes a connection manifold 2021 that provides connection interfaces between the conduits 2005a, 2005b to the therapeutic device 61 and the vacuum unit 2002, and between the vacuum unit 2002 and the therapeutic fluid reservoir 2026, via the fluid port 2025. The connection manifold 21 is illustrated by a dotted line in Figures 68 and 69 and replaces the connector 2009 shown in Figure 66. The manifold is described in more detail below.

[0212] As described, the treatment systems 2100, 2200, and 2300 include a reservoir 2006 for collecting fluid removed from the wound site 62, for example, wound exudate. In a preferred embodiment, the reservoir 2006 is located furthest from the wound and therefore downstream of the pump assembly 2015 to collect fluid removed from the wound after passing through the pump assembly 2015. In the shown embodiment, the reservoir 2006 includes a flexible bag. Alternatively, a rigid reservoir may be provided.

[0213] The reservoir 2006 comprises one or more air-permeable filters or vents 2006a provided in the wall of the reservoir, for example, a hydrophobic vent provided covering the opening of an impermeable membrane. The air-permeable filters or vents allow gas to pass through, thereby preventing a pressure rise in the reservoir that would hinder effective pumping. An exemplary reservoir has eight vents 2006a, each having a diameter of 8 mm and a pore size of 3 microns to maintain a high level of airflow through the system.

[0214] Blood clots, fibrin, and other coagulated fluids or tissue fragments can block the vent membrane, causing the bag to inflate with air introduced into the fluid pathway. This inflation may cause the bag to rupture and leak fluid, or it may prevent the pump from generating the required vacuum pressure by forcing the outlet valve open under excessive positive pressure.

[0215] To avoid these problems, highly salt-compatible sodium polyacrylate polymers, or other equivalent blood-compatible superabsorbent polymers, may be added to the reservoir to coagulate the blood and wound fluids within the bag. These polymers are available as free particles, suspended particles in a soluble PVA film pouch, or suspended polymers in a fabric / cloth-like medium. Using this polymer in conjunction with one or more vents on the bag avoids bag inflation and allows the fluid pathways of the treatment system to accommodate much more air as it is introduced into the system.

[0216] The pump assembly 2015 includes an inlet and an outlet and is driven by a motor. In one embodiment, the pump assembly 2015 may be substantially as described in PCT international application PCT / NZ2021 / 050205, and comprises a swash plate, a plurality of flexible chambers (diaphragms), a plurality of pairs of flexible valves, each pair of valves in fluid communication with its respective flexible chamber, and a pump inlet and an outlet.

[0217] The pump assembly 2015 includes a fluid passage through the pump from the pump inlet to the pump outlet. In a preferred embodiment, the exudate reservoir 2006 is located downstream of the pump assembly 2015. This means that fluid from the wound passes through the pump assembly 2015.

[0218] The pump assembly 2015 preferably comprises a high-capacity pump configured to maintain negative pressure while introducing a considerable amount of air into the treatment systems 2100, 2200, and 2300, with the air inlet valve 2018 open for a significant portion of the valve opening / closing cycle time. The high-capacity pump assembly 2015 is required to move the increased amount of air and lift the fluid from the wound 62 to the exudate reservoir 2006, while maintaining the negative pressure in the wound 62 at an effective treatment negative pressure level.

[0219] The air inlet valve 2018 may include an actuator such as a solenoid that is in electrical communication with a controller to drive the valve between an open position and a closed position. The air inlet valve 2018 does not operate as a pressure relief valve, i.e., the air inlet valve is not controlled to "force open" to limit the pressure at the wound. The air inlet valve is opened and closed based on a predetermined time, i.e., the control of the air inlet valve is time control rather than pressure control as will be described in more detail below.

[0220] The fluid inlet valve 2022 may include an actuator such as a solenoid that is in electrical communication with a controller to drive the valve between an open position and a closed position.

[0221] A dual-lumen catheter may be provided to connect between the vacuum unit 2002 and the treatment device 61. The catheter may have a circular outer wall. This catheter is preferred for wound treatment where the catheter must not open the wound and then must be removed. The round or circular outer wall allows the catheter to be rotated during removal to gently release tissue adhering to the side of the catheter that may cause discomfort to the patient.

[0222] In some alternative embodiments, the device 61 may be operably connected to one or more other devices implanted at respective different sites to treat the respective sites using the same pressure source.

[0223] System operation Here, the operation of the treatment system 2100 described above will be described with reference to FIGS. 70-80. The system 2100 includes a user interface 2014 that enables a user to operate the system. The user interface 2014 can provide visual (e.g., LED) and audio instructions to the user for system settings, and inputs, e.g., one or more buttons, enable, for example, turning the unit on / off, operating the pump, or selecting an operating mode. The controller provides system logic and control algorithms that communicate electrically with the air valve actuator, the pump motor, and the pressure sensors Pv, Pp to control the air inlet valve 2018 and the pump assembly 2015. The controller also communicates with the power management and sensor circuitry to manage the power supply and can provide battery charging instructions to the user via, for example, the user interface.

[0224] The controller is configured to operate the pump assembly 2015 to maintain negative pressure at the wound 62 via the wound treatment device 61 while opening and closing the air inlet valve. The air inlet valve 2018 is opened to introduce air into the wound site, while the pump assembly continues to move to maintain negative pressure at the wound.

[0225] Negative pressure treatment can result in a stagnant system even when the wound continues to produce exudate. In a stagnant system, the system is effectively sealed from the surrounding environment, and fluid transfer or flow from the wound to the exudate reservoir 2006 is not achieved. This can exacerbate system blockages due to coagulation of blood, fibrin, etc. at the wound and / or other locations within the system. The blockage ultimately results in the failure to provide negative pressure at the wound, invalidating the negative pressure treatment.

[0226] To avoid a stagnant system, the controller opens and closes the air inlet valve 2018 while continuously moving the pump assembly 2015 to maintain negative pressure at the wound.

[0227] For example, the treatment system 2100 is configured to open the air inlet valve 2018 to introduce air to the wound site while maintaining a vacuum pressure (first vacuum pressure) of at least 40 mmHg, preferably at least 50 mmHg, at the wound site 62 of the wound treatment device 61. In an exemplary embodiment, the treatment system can maintain a vacuum pressure of approximately 50 mmHg to 100 mmHg, or approximately 60 mmHg to 100 mmHg, or 70 mmHg to 100 mmHg, or 80 mmHg to 100 mmHg at the wound site / wound treatment device with the air inlet valve open and air being introduced to the wound. When the controller closes the air inlet valve, the pump continues to operate to maintain negative pressure at the wound. With the air valve closed, the vacuum pressure at the wound site 62 may be approximately 100 mmHg to 150 mmHg (second vacuum pressure).

[0228] Preferably, the vacuum pressure maintained in the wound healing device when the air inlet valve is open is at least a substantial portion of the vacuum pressure maintained in the wound when the air inlet valve is closed, or may be equal to the vacuum pressure maintained in the wound when the air inlet valve is closed. For example, the vacuum pressure maintained in the wound with the air valve open may be about 30% to 100% of the vacuum pressure maintained in the wound with the air valve closed, or about 50% to 100%, 70% to 100%, or about 80% of the vacuum pressure maintained in the wound with the air valve closed.

[0229] With the air inlet valve closed, the vacuum pressure in the wound may be approximately 20-50 mmHg higher than the vacuum pressure in the wound when the air inlet valve is open, or it may be equal to the vacuum pressure in the wound when the air inlet valve is open.

[0230] In a preferred embodiment, the system is configured to cycle the air inlet valve between an open and closed position while maintaining negative pressure in the wound. With the air inlet valve closed, the system quickly returns to a stagnant state. To avoid remaining in a stagnant state which could lead to blockage formation, the controller is configured to reopen the air inlet valve while maintaining negative pressure in the wound, and then close the air inlet valve again. The opening and closing of the air valve continues. Introducing air into the system while maintaining negative pressure in the wound facilitates the movement of fluid from the wound to the reservoir and reduces the risk of blockage. In some embodiments, the treatment system may be configured to keep the air inlet valve open and closed to achieve continuous pump operation, maintain fluid flow, and avoid remaining in a no-flow or stagnant state for extended periods.

[0231] In a preferred embodiment, the system is configured to achieve equilibrium with the air inlet valve 2018 open, such that the flow rate of air into the treatment system through the air inlet valve 2018 is equal to the flow rate of fluid (e.g., exudate) and air through the pump. In equilibrium, the vacuum pressure in the wound treatment device 61 is maintained at or reaches a steady state or a constant vacuum pressure level (first vacuum pressure). The system may achieve a constant vacuum pressure level after a short duration, e.g., a few seconds or less, e.g., 5 seconds or less. In some embodiments, in equilibrium with the air valve open, the pressure drop across the treatment device is substantially zero, and substantially all of the pressure drop between the system vacuum pressure and the ambient pressure occurs across the inlet throttling provided, for example, by the air inlet filter. In some embodiments, in equilibrium with the air inlet valve open, the pressure drop across the treatment device is constant. Introducing air into the wound can create a pressure drop across the wound site between the upstream and downstream sides of the treatment device, allowing fluid to move from the wound 62 to the reservoir 2006, thereby reducing the risk of coagulation and system occlusion.

[0232] With the air valve closed, the pump is controlled to maintain negative pressure in the wound, and the flow rate from the wound to the pump is proportional to the patient's wound response, i.e., the flow rate is proportional to the exudate produced in the wound. With the air inlet valve closed, the pump is controlled to maintain the vacuum pressure in the wound healing device at a steady state or a constant vacuum pressure level (second vacuum pressure). Again, the system can achieve a constant vacuum pressure level after a very short duration, e.g., a few seconds or less, e.g., 5 seconds or less. As described above, the first vacuum pressure is less than or equal to the second vacuum pressure.

[0233] The steady-state vacuum pressure in the wound treatment device 61 with the air inlet valve 2018 open may be less than the steady-state vacuum pressure in the wound treatment device with the air inlet valve closed. However, the vacuum pressure in the wound treatment device 61 with the air inlet valve open is sufficient for effective negative pressure therapy. As described above, the first vacuum pressure is at least a substantial part of the second vacuum pressure and may be equal to the second vacuum pressure. Therefore, periodically opening and closing the air inlet valve while running the pump to continuously achieve therapeutic negative pressure not only improves exudate removal and reduces the risk of system occlusion, but also maintains a negative pressure environment in the wound for effective wound treatment.

[0234] Cycle the opening and closing of an air inlet valve while maintaining negative pressure in the wound achieves a reduced fluid density at the wound site through the introduction of air. Often, for example, when the patient is standing or upright, there is a difference in height at the wound site. This difference in height in the wound can result in fluid flowing only to the upper part of the wound, while remaining stationary at the bottom of the wound. By introducing air across the wound site, the air reaching the bottom of the wound can lift the fluid from those bottom parts, improving fluid movement throughout the wound.

[0235] The introduction of air essentially allows the system to act like an air pump, enabling lower-density fluids to move "upward" or against gravity.

[0236] The inventors have additionally identified a preferred operating mode in which the air valve operates between an open and closed position while maintaining negative pressure in the wound, in order to introduce air into the system at a flow rate that achieves a “bubble flow” or “slug flow” from the wound site to the reservoir. Figure 70 illustrates the range of flow types in fluids, including both liquid and gaseous states. Introducing a large amount of air by leaving the air inlet valve open for an excessively long time may result in an annular type of flow in which exudate flows along the inner wall of the conduit and air flows through the center of the conduit. This may cause the exudate to stagnate on the wall of the conduit, which may lead to the solidification of the fluid. The layer of solidified fluid may increase over time and lead to blockage. By cycling the opening and closing of the air inlet valve, the liquid exudate may reform a uniform column in the flow path of the system when the air valve is closed, and the subsequent opening of the air inlet valve to introduce air may result in bubbles or slug of air passing through the exudate. The air valve is closed again before annular flow is achieved. The inventors believe this results in improved exudate removal and reduced blockage.

[0237] Herein, with reference to Figures 71 to 75, an exemplary embodiment of a cycle of opening and closing the air inlet valve during NPT is described. As illustrated in Figure 71, the controller is configured to implement an airflow mode or state in which the air inlet valve is open and the pump operates to achieve negative pressure at the wound, and a non-airflow mode or state in which the air inlet valve is closed and the pump operates to achieve negative pressure at the wound. In the exemplary embodiment, the non-airflow states include a pressurized state, a hold state, and a timeout state.

[0238] Referring to Figure 72, in an airflow state, the controller opens the air inlet valve to allow air to enter the system upstream of the treatment device and operates the pump to achieve a pressure threshold. For example, if the pressure sensed by the pressure sensor Pp downstream of the treatment device is below the pressure threshold, the controller operates the pump (turns the pump on). In other words, if the pressure at Pp is equal to or greater than the threshold pressure, the controller turns the pump off.

[0239] In the illustrated embodiment, the downstream pressure threshold (Pp) of the treatment device is a portion of the upstream pressure threshold (Pv) of the treatment device when the air inlet valve is closed. In the illustrated embodiment, the downstream pressure threshold (Pp) of the treatment device is 80% of the upstream pressure threshold (Pv) of the treatment device when the air inlet valve is closed. For example, when the air inlet valve is closed, the upstream pressure threshold at Pv of the treatment device is 100 mmHg, and in an airflow state with the air inlet valve open, the pressure threshold at Pp is 80 mmHg.

[0240] The pump can be repeatedly switched on and off, for example under PID control by a controller, to maintain vacuum pressure downstream of the wound healing device with the air inlet valve open. Preferably, the system is configured to achieve a threshold pressure downstream of the healing device at Pp in a very short time, i.e., within a few seconds, for example, within 5 seconds. The air inlet valve remains in the open position for a certain period of time. When the air inlet valve is open, the pressure at the wound is maintained constant. In the illustrated embodiment, the air inlet valve remains in the open position for 14 seconds. After 14 seconds, the controller closes the air inlet valve, and the controller transitions to a pressurized state without airflow.

[0241] The parameters of the airflow state described above are provided as examples. In some embodiments, the system may not have a pressure sensor Pp downstream of the treatment device. The pump may have a suitable capacity so that the pump is moved at a predetermined speed corresponding to a particular system performance to achieve a known or acceptable pressure level (first vacuum pressure) in the wound treatment device with the air inlet valve open. Additionally or alternatively, the system may include a pressure relief valve for introducing air into the system at the pump inlet to ensure that the vacuum pressure generated by the pump does not increase excessively high. However, in a preferred embodiment, the system includes a pressure sensor Pp, and the controller operates the pump so that the pressure does not increase above a predetermined pressure threshold, 80 mmHg in the above example. Other pressure thresholds are possible depending on the desired treatment plan. Preferably, the controller implements PID control to achieve precise control of the pump, and therefore control of the vacuum pressure in the wound. The controller may use pulse-width modulation (PWM) or pulse-synchronous modulation methods in controlling the pump motor.

[0242] As shown in Figures 66-69, in exemplary embodiments, the pressure sensor Pv is located on the ambient side of the filter. The sterile filter 2019 presents a known pressure drop to prevent the vacuum pressure in the treatment device from dropping to ambient pressure when the air inlet valve is open. With the pressure sensor Pv located on the ambient side of the filter, the sensor Pv essentially measures the ambient pressure when the air inlet valve is open. Therefore, when the air inlet valve is open, the pressure sensed by the sensor Pv is not used to control the pump, and the pump will operate until the pressure sensed by Pp increases above a pressure threshold. In some embodiments, the pressure at Pp will not reach the pressure threshold when the valve is opened. The pump may operate continuously when the air inlet valve is open, which is less desirable.

[0243] Referring to FIG. 77, in the pressurized state, the air inlet valve is closed and the controller operates the pump to achieve a pressure threshold and achieve a known or acceptable vacuum pressure (second vacuum pressure) in the wound treatment device. With the air valve closed, the vacuum pressure in the wound treatment device can increase compared to the vacuum pressure achieved in the air flow mode. In the illustrated embodiment, when the pressure sensed by the pressure sensor Pv upstream of the treatment device is less than 100 mmHg and the pressure sensed by the pressure sensor Pp downstream of the treatment device is less than 150 mmHg, the controller operates the pump. In other words, when the pressure Pv is 100 mmHg or more, or the pressure Pp is 150 mmHg or more, the controller turns off the pump.

[0244] The system can be configured to achieve the threshold pressure after a very short duration of closing or opening the air inlet valve, i.e., within a few seconds, for example, within 5 seconds. With the air valve closed, the system is closed or sealed, so the system very quickly reaches a stagnant or non-flowing state with zero pressure drop across the treatment device, thus the pressure at Pv = the pressure at Pp. In the illustrated embodiment, since the pressure threshold at Pv is less than the pressure threshold at Pp, the controller controls the pump based on the upstream pressure sensor Pv, which is the lower of the two pressure thresholds. However, a pressure drop through the system can occur when coagulation materials such as tissue fragments and / or fibrin accumulate in the wound treatment device and / or the pump, in which case a pressure difference can develop between the upstream and downstream sides of the treatment device as measured by the sensors Pv and Pp. Before the lower threshold is reached upstream of the treatment device, system constraints can cause the system pressure to reach the upper threshold downstream of the treatment device, in which case the pump is controlled to the upper pressure threshold at Pp based on the downstream pressure sensor Pp.

[0245] When the pressure threshold is reached, the controller turns off the pump and transitions to a hold state. The pressurized state includes a timeout check so that if the pump does not reach the pressure threshold (e.g., Pp) within 120 seconds, the motor is turned off and the controller transitions to a timeout state. This can occur due to other failure modes, such as blockage or leakage in the system.

[0246] Referring to Figure 74, in the holding state, the controller maintains the air inlet valve in the closed position and keeps the pump running, maintaining the desired or acceptable vacuum pressure in the wound healing device by turning the pump on and off under PID control to achieve, for example, a desired pressure threshold at Pv or Pp. The controller maintains the vacuum pressure with the air inlet valve closed for a certain period of time. In the illustrated embodiment, the air inlet valve is closed for 20 seconds.

[0247] After 20 seconds, the controller returns to airflow mode, and the cycle of opening and closing the air inlet valve is repeated. The opening and closing of the air inlet valve can be cycled continuously to achieve the benefits described above.

[0248] The exemplary embodiment described above provides an air inlet valve open time of 14 seconds and an air inlet valve closed time of 20 seconds. These times are examples, and alternative times may be implemented. However, it should be noted that the air inlet valve is open for a substantial portion of the entire opening and closing cycle. In this embodiment, the entire opening and closing cycle, or "cycle pitch," is 34 seconds, and the air inlet valve is open for 14 seconds of the 34 seconds, or about 40% of the entire cycle. In some embodiments, the air inlet valve is open for at least 10% of the cycle pitch, or at least 20% of the cycle pitch, or at least 30% of the cycle pitch, or at least 40% of the cycle pitch. For example, the air inlet valve open time may be approximately the same as the closing time (50% of the cycle pitch). In some embodiments, the air inlet valve may be open for more than 50% of the entire cycle.

[0249] The exemplary system configuration described above provides a cycle time of 34 seconds. However, longer or shorter cycle times are possible. As described above, the ideal is to open and close the air inlet valve as necessary to achieve a slug or bubble flow from the wound site to the reservoir while maintaining negative pressure at the wound. The maximum valve cycle time may be one minute or several minutes. However, the air inlet valve should be open for at least about 10 seconds at the above pressure to ensure that sufficient air is introduced into the system. The air inlet valve may be open for 10 to 40 seconds in each air inlet valve opening and closing cycle.

[0250] The time the air inlet valve is open or closed depends on the air inlet flow restriction, pump capacity, treatment device configuration, and the length and diameter of the supply and exudate conduits. The system components and control parameters described above are provided as examples. However, the inventors believe that the system parameters should be selected to allow the air inlet valve to be open for a substantial duration while maintaining the negative pressure in the wound at a level useful for negative pressure treatment of the wound.

[0251] Referring to Figure 75, an exemplary embodiment includes a time-out state for safely managing situations where the system cannot reach the intended negative pressure level. As described above with reference to Figure 73, if the system cannot pressurize when the air inlet valve is closed after a predetermined time (e.g., 2 minutes), the controller enters a time-out state. The controller pauses pump operation for 30 seconds and increments the time-out counter. If the time-out counter is below a predetermined count threshold, the controller returns to the pressurized state and attempts to pressurize the wound healing site. If the time-out counter threshold is reached, the controller returns to the airflow state. As described above, introducing air can reduce blockages. The system may fail to pressurize due to blockages. Returning to the airflow state can remove blockages before returning to the pressurized state.

[0252] In some embodiments, the treatment system may implement other control parameters not shown in Figures 71-75. For example, in some embodiments, the system may include a pressure sensor Pv upstream of the treatment device and a pressure sensor Pp downstream of the treatment device. The controller may operate the pump and / or air inlet valve based on the pressure difference measured between the two pressure sensors. For example, the controller may open the air inlet valve when the pressure difference increases above an upper threshold or exceeds the upper threshold for a predetermined period of time. The system pressure difference may indicate blockage in the system, particularly when the air inlet valve is closed. With the air valve closed and the system stagnant, the pressures upstream and downstream of the treatment device should be substantially equal. The controller may close the air valve when the pressure difference decreases below a lower threshold or remains below the lower threshold for a predetermined period of time. The controller may stop the pump and / or airflow state when the pressure difference increases above an upper or maximum threshold.

[0253] As described above with reference to Figures 68 and 69, in some embodiments the system is configured to introduce a therapeutic fluid into the wound. In the system of Figure 68, the controller may be configured to operate a therapeutic fluid inlet control valve 2022 to introduce the therapeutic fluid in a manner similar to the operation of the air inlet valve 2018. The therapeutic fluid reservoir 2026 is preferably at ambient pressure.

[0254] The controller operates the pump while opening the fluid inlet valve 2022 to maintain negative pressure in the wound healing device and draw the healing fluid into the device. In a preferred embodiment, the system is configured such that with the fluid inlet valve 2022 open, the system achieves equilibrium and the flow rate of the healing fluid from the healing fluid reservoir 2026 into the healing system is equal to the flow rate of the fluid (e.g., exudate and healing fluid) passing through the pump. In equilibrium, the vacuum pressure in the wound healing device is maintained at or reaches a steady state or a constant vacuum pressure level (i.e., a third vacuum pressure). The system may achieve a constant vacuum pressure level after a very short duration, e.g., a few seconds or less, e.g., 5 seconds or less. In a preferred embodiment, with the fluid inlet valve open and in equilibrium, the overall pressure in the healing device is substantially zero.

[0255] When the fluid inlet valve is open, the controller may operate the pump to achieve the same pressure in the treatment device as the treatment system achieves when the air inlet valve is open.

[0256] With the fluid inlet valve closed, the pump is controlled to maintain negative pressure in the wound. With the fluid inlet valve closed, the pump may be controlled to maintain the vacuum pressure in the wound healing device at a steady state or a constant vacuum pressure level (fourth vacuum pressure). Again, the system may achieve a constant vacuum pressure level after a very short duration, e.g., a few seconds or less, e.g., five seconds or less. When the fluid inlet valve is closed, the controller may operate the pump to achieve the same pressure in the healing device as the healing system achieves when the air inlet valve is closed.

[0257] The steady-state vacuum pressure in a wound healing device with the fluid inlet valve open may be less than the steady-state vacuum pressure in a wound healing device with the fluid inlet valve closed. However, the vacuum pressure in a wound healing device with the fluid inlet valve open is sufficient for effective negative pressure therapy. Therapeutic fluid is not introduced under positive pressure. Therefore, opening and closing the fluid inlet valve while operating the pump to continuously achieve therapeutic negative pressure not only maintains a negative pressure environment in the wound for effective therapy, but also provides introduction of therapeutic fluid, removal of exudate, and reduction of the risk of system occlusion to improve therapy.

[0258] The amount of therapeutic fluid administered to the system can be controlled based on the time the fluid inlet valve is open. A flow restriction (such as a retractable orifice) may be placed between the therapeutic fluid reservoir 2026 and a Pv pressure sensor located upstream of the wound healing device. The resulting pressure drop across this restriction may allow the fluid velocity to be determined from the resulting pressure drop measured by the sensor Pv, and the total amount of therapeutic fluid administered to be calculated. Alternatively, the therapeutic fluid inlet valve may be opened until a differential pressure threshold is achieved, or until it is achieved over a certain period of time, or the valve may be opened over a predetermined period of time. The therapeutic fluid inlet valve is preferably opened when the air inlet valve is closed.

[0259] Referring to the embodiment in Figure 69, the system does not have a therapeutic fluid inlet valve controlled by a controller. The system administers therapeutic fluid during the therapeutic negative pressure, as the vacuum pressure in the wound draws the surrounding therapeutic fluid into the system. When the air valve is opened, air flows into the therapeutic device, and the flow of air into the system tends to stop the flow of fluid from the therapeutic fluid reservoir due to the much lower density of air compared to the density of the therapeutic fluid. When the air inlet valve is closed, the negative pressure in the wound draws fluid from the therapeutic fluid reservoir into the system, causing it to overflow into the wound. When the pump maintains vacuum pressure in the wound, the therapeutic fluid passes through the therapeutic device and wound, and is sent through the pump to the reservoir. When the air valve is reopened, the flow of therapeutic fluid stops again, creating a pressure difference that moves the fluid, including the therapeutic fluid and exudate, out of the wound. Thus, circulating the air inlet valve can also achieve the addition of therapeutic fluid to the wound and the removal of therapeutic fluid from the wound in a periodic manner. The amount of therapeutic fluid added depends on how long or how much air is introduced. The amount of therapeutic fluid introduced into the system may be proportional to the amount of air introduced into the system.

[0260] Here, exemplary embodiments of the system shown in Figure 68 are described with reference to Figures 76-79. As illustrated in Figure 76, the controller is configured to implement fluid supply modes or states in addition to the airflow states described above. The controller implements a non-supply / non-airflow mode, in which the air inlet valve and the treatment fluid valve are closed and the pump is operated to achieve negative pressure at the wound. In the exemplary embodiment, non-airflow states include pressurized, held, and time-out states.

[0261] The airflow and pressurized states in Figure 76 are as described above with reference to Figures 72 and 73. When the airflow and pressurized states in Figures 68 and 69 are changed, the controller implements the fluid supply and holding state in Figure 77.

[0262] Referring to Figure 77, in the holding state, the controller maintains the air inlet valve in the closed position and keeps the pump running, maintaining the desired or acceptable vacuum pressure in the wound healing device by turning the pump on and off under PID control, for example, to achieve a desired pressure threshold (at Pv or Pp). The controller maintains the vacuum pressure with the air inlet valve closed for a certain period of time, for example, 20 seconds. After 20 seconds, the controller turns off the pump and checks to see if a fluid supply state is required. If a fluid supply state is not required, the controller returns to airflow mode and the cycle of opening and closing the air inlet valve is repeated as described above with reference to Figure 71. The controller implements a fluid supply state if a healing fluid supply has not been provided for a predetermined period of time, for example, 8 hours, or if a user-set fluid supply cycle time is triggered, or if the user manually requests a fluid supply, for example, by pressing a button on the user interface of the vacuum unit.

[0263] The time required to initiate the fluid supply state is much longer than the air inlet valve opening / closing cycle time. For example, the air inlet valve cycle time may be less than one minute, while the time spent in the fluid supply state may be more than one hour.

[0264] Referring to Figure 78, in the fluid supply state, the controller opens the fluid valve to allow the therapeutic fluid to flow from the therapeutic fluid reservoir to the system upstream of the therapeutic device and operates the pump to achieve a pressure threshold. The controller operates the pump when the pressure sensed by the upstream pressure sensor Pv of the therapeutic device is less than 100 mmHg and the pressure sensed by the downstream pressure sensor Pp of the therapeutic device is less than 150 mmHg. The control of the pump when the therapeutic fluid valve is open may be the same as or similar to the control of the pump when the air inlet valve is open, as described above. In the illustrated example, the controller keeps the fluid valve open for 10 seconds, but other times are also possible. The controller may close the fluid valve and allow a fluid contact residence time, allowing the fluid introduced into the wound to overflow or remain at the wound site for a set time. The controller may allow user input to set a residence time of 0 to 10 minutes or other times. Following a delay to allow fluid contact within the wound, the controller enters a flushing cycle to flush the therapeutic fluid out of the wound. In the illustrated embodiment, the controller repeats the flushing cycle three times, but the controller may perform the flushing cycle one, two, or more than three times. In the illustrated embodiment, the controller repeats the fluid supply state three times before returning to the pressurized state, but the controller may perform the fluid supply state one, two, or more than three times.

[0265] Referring to Figure 79, in the flush cycle, the controller repeats the fluid supply state, continuing the fluid supply state as needed as shown in Figure 78, and steps through the pressurized state, held state, and airflow state as described above with reference to Figures 73 and 74 before opening the fluid valve again. At the end of the fluid supply state, the controller returns to the pressurized state in Figure 73. The system continues to pressurize, hold the pressure, and cycle the opening and closing of the air inlet valve as described above.

[0266] In the illustrated embodiment, the fluid inlet valve is open for 10 seconds and closed for 102 seconds in each opening and closing cycle of the fluid inlet valve. The closing time depends on the residence time and the combined flush cycle execution time. In the illustrated embodiment, the fluid supply state includes three flush cycles. With each flush cycle requiring 34 seconds and an exemplary residence time of zero, in the illustrated example, the fluid supply valve is closed for a total of 102 seconds. In the illustrated example, the fluid inlet valve is open for approximately 10% of the cycle pitch. The fluid inlet valve may be open for at least 5% of the cycle pitch, or at least 10% of the cycle pitch, or at least 20% of the cycle pitch.

[0267] The fluid supply and flushing procedure provides therapeutic fluid to the wound while maintaining negative pressure, and uses air introduction to flush the therapeutic fluid from the wound, thereby removing fluid and exudate from the wound. As described above, several types of therapeutic fluid flushing may be provided. This procedure reduces stagnant fluid within the wound, thereby reducing blockage in the system and ensuring that negative pressure is continuously applied to the wound site.

[0268] The operation of systems 2100, 2200, and 2300 may be via a user interface 14 that allows the user to selectively operate the system. The user interface may provide the user with visual (e.g., LEDs) and / or audio instructions to communicate system settings. The user interface 14 may include several buttons for starting or stopping the delivery of negative pressure to the connected wound healing device 61, turning the unit power on or off, silencing an audible alarm, and / or connecting the device to a remote wireless receiving device to transmit data regarding the operation or status of the system.

[0269] The controller may provide system logic and control algorithms that communicate electrically with actuators for the air valve 2018, actuators for the dressing control valve 2029, the motor for the pump 2015, and pressure sensors Pv and Pp. The controller 2017 is configured to control the air inlet valve 2018 and the pump assembly 2015 based on readings from pressure sensors Pv and Pp. The controller may also communicate with power management and sensor circuits to manage the power supply or provide battery level warning alarms.

[0270] The controller 2017 is configured to operate the pump assembly 2015 to maintain negative pressure in the wound 62 via the wound healing device 61 while opening and closing the air inlet valve 2018. The air inlet valve 2018 is opened to introduce air into the wound site, as described elsewhere in this specification, while the pump assembly continues to operate to maintain negative pressure in the wound.

[0271] Negative pressure therapy can result in a stagnant system that exacerbates system occlusion caused by coagulation of blood, fibrin, etc., in the wound and / or elsewhere in the system. This occlusion can ultimately lead to failure to deliver negative pressure at the wound, reducing the effectiveness of negative pressure therapy.

[0272] The controller may be configured to adapt to expected changes that may occur in the system in response to changes occurring in the wound healing site 62 and the implanted healing device 61. It has been found that when the healing device is subjected to repeated cycles through pressurized, held, and airflow states, the pressure difference between the Pv pressure sensor and the Pp pressure sensor may occur in response to changes in the healing site 62 and / or the implanted wound healing device 61 as a result of internal tissue growth, accumulation of wound debris, and many other factors.

[0273] In response to these dynamic changes, the system adjusts the target pressure level applied to the Pv pressure sensor between pressure sites to compensate for changes in the therapeutic device 61. For example, if the motor stops as a result of the Pp pressure sensor exceeding 150 mmHg, the system may be configured to reduce the target vacuum pressure level by 10 mmHg, for example, from target 1 (100 mmHg) pressure applied to the Pv pressure sensor to target 2 pressure of 90 mmHg, before proceeding to the holding state. If the pressure drop across the implanted therapeutic device 61 increases again, the system continues to reduce the target level by one step until the Pv pressure level reaches a pressure below 60 mmHg (target 5).

[0274] [Table 1]

[0275] When the pressure level measured by the Pv pressure sensor reaches this level, the system will cease transitioning from the holding state to the airflow state, returning the system to a continuous vacuum pressure level system.

[0276] If the vacuum pressure level at Pv drops below 60 mmHg (Target 5) during the holding state and then returns to 90 mmHg (Target 2), the system will resume the airflow state, and the cycle between holding, airflow, and pressurization will resume.

[0277] The systems described herein may provide significant benefits, including, but not limited to, one or more of the following: • Improved fluid removal from the wound site, providing enhanced healing benefits such as reduced edema due to the removal of excess exudate. • Reduce the risk of blockages forming within the system. • Maintain effective negative pressure in the wound, even while adding air, to ensure effective treatment. • If there is a difference in height in the wound, remove the exudate from the lower part of the wound. • Low power consumption, making it suitable for use in portable wound healing systems. • To ensure effective treatment, apply the therapeutic fluid to the wound while maintaining effective negative pressure in the wound. • To improve treatment throughout the entire treatment space, provide negative pressure to a larger portion of the treatment space. • The configurability of systems with and without the provision of therapeutic fluid to wounds. • Ease of providing a sterile interface between the air inlet and the wound site.

[0278] Although the present invention has been described as an example, modifications and alterations can be made without departing from the scope of the present invention as defined in the claims.

Claims

1. 1. A bioabsorbable device for implantation within a patient's body for administering fluid and / or negative pressure to a treatment site, the device comprising a bioabsorbable resilient truss for holding two tissue surfaces apart, the truss comprising: two flexible elongated wall members wound in a manner to define a channel, the two elongated wall members periodically crossing each other at a plurality of crossing nodes; at least two flexible, elongated bracing members, each bracing member looping around the wall member or the wall member looping around the respective bracing member, the bracing members mechanically coupled to the two elongated wall members at a plurality of the crossing nodes.

2. The device of claim 1 , wherein the bracing members extend generally longitudinally along sides of the channel.

3. The device of claim 2 , wherein the bracing members are provided on opposite sides of the channel.

4. 3. The device of claim 1 or 2, wherein the wall members are rolled to form a generally tubular device having porous walls such that fluid from the treatment site can exit the channels and / or fluid can be delivered from the channels to the treatment site.

5. The device of any one of claims 1 to 4, wherein each bracing member comprises a main filament that forms at least a complete 360 ​​degree loop around the wall member at the respective crossing node.

6. 6. The device of claim 5, wherein the main filament of each bracing member loops 720 degrees around the wall member at the respective crossing node.

7. 7. The device of claim 5 or 6, wherein each bracing member further comprises a secondary filament twisted around the primary filament.

8. 8. The device of claim 1, wherein each bracing member comprises two filaments twisted together, the wall member being held between the two filaments at the respective crossing nodes.

9. The device of claim 8 , wherein there is at least one complete twist of the filament between adjacent interconnected cross nodes.

10. 10. The device of claim 1, wherein a first one of the wall members is generally helical having a first pitch length and a second one of the wall members is generally helical having a second pitch length that is the same as the first pitch length.

11. The device according to any one of claims 1 to 10, wherein the two wall members are wound in opposite directions.

12. A device according to any preceding claim, wherein a first one of the wall members is a left side wall member and a second one of the wall members is a right side wall member.

13. A device according to any preceding claim, wherein each wall member is wound with a pitch length of from about 2 mm to about 10 mm.

14. The device of claim 13 , wherein each wall member has a pitch length of about 4 mm.

15. The channel is at least 16 mm 2 The device according to any one of claims 1 to 14, having a cross-sectional area of

16. The device of any one of claims 1 to 15, further comprising a flexible bioabsorbable sheet, said sheet forming at least a portion of a wall of said channel.

17. The device of claim 16 , wherein the flexible bioabsorbable sheet is wrapped around the truss.

18. The device of claim 17 , comprising a plurality of openings in the flexible bioabsorbable sheet to allow fluid flow into the channels.

19. 1. A system for draining fluid from or delivering fluid to a treatment site within a patient's body, comprising: (i) a device according to any one of claims 1 to 18; and (ii) a conduit releasably coupled to either the port or a fluid impermeable covering of the device; (iii) a reservoir located outside the patient's body, the reservoir in fluid communication with the conduit for receiving fluid from or delivering fluid to the conduit; and (iv) a pressure source coupled to the conduit for delivering positive or negative pressure to the device.

20. 20. The system of claim 19, wherein the pressure source is capable of delivering negative pressure to the device such that fluid is expelled from the treatment site into the device and transported through the conduit to the reservoir.

21. The system of claim 20 , wherein the negative pressure source is configured to draw a treatment fluid through the device.